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Delayed Hypersensitivity
·
Specific inflammatory immune reaction elicited by antigen in the
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That part of the structure of an antigen that binds to the
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xiii

LIST OF DEFINITIONS
(continued)
bind the Fe portion of immunoglobulins of the IgG class.
Graft-Versus-Host Reaction
The pathological reactions caused by transplantation of
immunocompotent T lymphocytes to an immunocompotent host.
The host is unable to reject the T lymphocytes and becomes the
target of attack by them.
H-2
The major histocompatibility complex in the mo~'se.
H-2K and H-20
Loci in the MHC in mice coding for histocompatibility antigens
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molecule and the one determining the class of the immunoglobulin.
Helper Cells
A class of specific T cells that are necessary to help B cells
produce antibody to thymus-dependent antigens.
HLA
The major Histocompatibility complex in man.
HLA-A, HLA-B, and HLA-C
Three distinct genetic loci in the MHC of man coding for the
major histocompatibility antigens.
HLA-D
A region of the MHC of man coding for antigens expresses primarily
on B cells and that stimulate the specific proliferation of
allogenic T cells in culture.
Humoral Immunity
Immune phenomena involving the production of specific antibodies.
Hypersensitivity
Widely used term which applies to those immune phenomena that are
damaging in some way to the host animal.
Ia
Histocompatibility antigens found primarily on B cells, but also
on some macrophages, T cells, and skin. They are coded for in the
I region (see Figure 1) of the MHC.
Idiotype
An antigenic determinant on a specific antibody that is characteristic of that antibody and different from others even of the
same Isotype and Allotype; idiotypes are usually located in or
near the combining site.
11

xiv

11

LIST OF DEFINITIONS
(continued)
Immunogen
A molecule that elicits an immune response.
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I Region
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are encoded.
I-A, I-B, I-C, I-E, and I-J
Subregions of the I region of the mouse H-2 complex
Isogenic
Originating from the same individual or the same inbred strain.
Isotype
The class or subclass of an immunoglobulin, common to all members
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K Cell
A class of cells, thought to be lymphocytes which are able to
mediate ADCC.
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Keyhole Limpet Hemocyanin- a strong thymus-dependent antigen
often used in hapten-carrier conjugates.

Any of a number of plant products that bind to cells, usually by
nature of a combining site for specific sugars.
Light Chain
The lower molecular weight polypeptide chain present in all
immunoglobulin molecules.
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functional classes of T cells.
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A group of substances produced by lymphocytes having diverse
effects on other cells.
Macrophage·
A ubiquitous phagocytic cell found in tissues and blood.
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CHAPTER I
INTRODUCTION
lA.

Review of the Related Literature

IA-1.

Division of Immunological Responsiveness
The first evidence for a division of immunological

responsiveness came from the work of Glick and Chang (1)
when they accidently discovered that the bursa of Fabricius,
a lymphoepithelial organ found exclusively in
important in antibody production.

bir~(2),

was

In 1962, Miller (3)

discovered that neonatal thymectomy in virus-induced leukemic
mice caused a severe depletion of -lymphocytes and a serious
impairment of the immune response to both injected cellular
antigens and skin grafts.

Warner et

~·

(4) was the first to

demonstrate a clear division of immunological function.

He

proposed that the bursa of Fabricius produced cells which
differentiated into antibody-producing clones, whereas the
thymus gave rise to cells responsible for homograft rejection.
Roitt et

~·

(5) in 1969 coined the terms 11 T-lymphocytes or

thymic-dependent lymphocytes .. , and 118-lymphocytes or bursaequivalent lymphocytes ...

Since then, T-lymphocytes have

been shown to be involved in cell mediated responses, such as
homograft rejections; whereas B-lymphocytes are involved in

1

2

humoral responses (antibody production).
With the advent of new laboratory techniques in the
1970's, it became possible to separate T-lymphocytes from
8-lymphocytes

~n

the basis of physical and chemical

differences (6-10).

Table 1 contains a list of differences

found between T- and 8-lymphocytes.in mice.
IA-2.

Subpopulations ofT-lymphocytes
T-lymphocytes or T-cells display an extraordinary

degree of functional heterogeneity.

They have been shown

to generate cytotoxic responses to alloantigens (11-13),
display helper (13,14) and suppressor (15-20) effects on
cell-mediated responses, and they help .B cells produce
antibody to thymus-dependent antigens (21-23).

As a result

of this broad specificity, various groups investigated the
possibility that more than one type ofT-cell existed.
The early work seemed to suggest that T-cells were
a homogenous, multipotent population.

Studies in which

T-lymphocytes were exposed to various doses of mitogenic
substances (e.g. concanavalin A and phytohemagglutinin
-M or -P) showed that the T-cell response elicited was dose
dependent.

Rich and Pierce (22-24) have shown that the

addition of submitogenic amounts of concanavalin A (con A)
or phytohemagglutin in (PHA) elicits an "enhancing or
helper effect", whereas mitogenic amounts of either mitogen

3

10
TABLE 1
Comparison ofMouse BandT Lymphocytes

B Cells

Properties

T Cells

Differentiation

Bursa of Fabricius
(in birds) or
lymphoid organ
equivalent in mammals

Ag-binding receptors
on the cell surface

Abundant Ig.(s)
(restricted to one
isotype, one allotype,
and one idiotype per
cell) •

a

Cell surface antigens:
Thetaaa
TLb
Lye

+
+
+ (plasma cells)

H-2 Transplantation
antigense

+

15
10
15
35
Abundant
Rare

Functions
Secretion of AntiYes (large lymphocytes
body molecules
and plasma cells
Helper function
No
(reacts with
"carrier" moities
of the immunogen
Effector cell for
No
cell-mediated immunity
immunity
Distribution in lymph
nodes and spleen:

Nature of specific
receptors is
uncertain. Ig(s)
are sparse.

+

pcd

Approximate frequency
(%) in:
Blood
Lymph (thoracic duct)
Lymph node
Spleen
Bone Marrow
Thymus

Thymus

Clustered in follicles
around germinal centers
continued on following page

+

85

90
85
65
Few
Abundant

No
Yes

Yes

In interfollicular areas

4

(continuation)
Properties
Susceptibility to
inactivation by:
X-irradiation
Corticosteroids
Antilymphocyte
serum(ALS)

B Cells

T Cells

+t-

+
+

+

-H-+t

++-I+

a

Ig(s) is an abbreviation for immunoglobulins
aa

Theta occurs at high levels in the thymus and brain. Two
allotypes are known: theta-AKR (in AKR and a few other
inbred mouse strains), and theta-C3H (in C3H, BALB/c,
and most other mouse strains).
b

TL is present on normal thymus cells of only some mouse
strains (TL+), but is present on leukemic lymphocytes
of TL+ and TL- strains.
c

Ly is present on thymus cells and circulating lymphocytes,
but absent from all nonlymphoid cells. There are two
loci: Ly-A and a second one with linked Ly-B and Ly-C;
two alleles are known at each.
d

PC is present on plasma cells(including myeloma cells).
e

H-2 histocompatibility Ags. BandT cells also differ
in ability to absorb Igs: B cells, but not T cells, bind
Ag-Ab complement (C) complexes through surface sites that
are specific for activated third component of C (C3).
Other sites on B cells bind aggregated Igs (cross-linked,
for instance by Ag), probably through specific reaction
with the Fe domains of the aggregated molecules.

results in a "suppressive effect".

Thus, they reasoned the

same population ofT-cells were capable of performing both
functions, by responding differentially to different
concentrations

~f

con A.

However, it has subsequently been

shown that "helper T-cells" and "suppressor T-cells" are
equally activated by con A (25); and that the helper response
is masked by the suppressive effect (25).
Evidence that distinct subsets ofT-lymphocytes exist
come from studies which probe differences in the cell surface
(13,26-44), sensitivity to radiation (38,45-49) and chemical
substances (38,50-52), and their distribution in different
animal tissues (37).
Peripheral T-cells in mice can be. subclassified into
three types ofT-cells based on the expression of gentically
controlled surface components of cells undergoing thymusdependent differentiation (13,26,27).

These surface components

are referred to as Ly-1, Ly-2, and Ly-3.

Each Ly system

comprises a genetic locus, Ly-1 on chromosome 19, Ly-2 and
Ly-3 found closely linked on chromosome 6, and each with two
alternate alleles.

Approximately fifty percent of the

peripheral T-cells express the phenotype Ly 1,2,3, thirtythree percent the phenotype Ly-1, and five to ten percent the
phenotype Ly-2,3.

Functional studies indicate Ly-1 T-cells

elicit helper response, while Ly-2,3 elicits both suppressor
and cytotoxic responses (25,28).

Recently it has been shown

5

that suppressor T-cells can be differentiated from cytotoxic
T-cells by the presence of an additional surface component,
an I-J antigen (29), coded for the I-J subregion of the !region of the major histocompatibility complex in mice (30-32).
The I region of the major histocompatibility complex or H-2
in mouse (HLA in humans) controls surface antigen which
stimulate the mixed lymphocyte reactions (MLR), a proliferative
response ofT-cells in culture to allogenic lymphocytes, and
graft-versus-host reactions (32).

Figure 1 (30) depicits the

genetic map of the H-2 complex.
Recently, a new technique of raising monoclonal
antibodies reactive to a specific cell surface determinants
has been applied to characterizing human T-cell subclasses.
A series of the monoclonal antibodies (T 1-T10 ) have been
developed which are reactive with thymocyte and peripheral
T lymphocyte cell surface antigens.

T-cells carrying the cell

surface antigens (T 1+,T 3+,T 4+) have been shown to have an
enhancing (helper) effect in T-cell-T-cell, T-cell-s-cell,
and macrophage interactions (33,34); whereas cells of the
+ + +
phenotype T1 ,T 3 ,T 5 have been shown to be cytotoxic (34,35)
and suppressive (34,35).
Thus, it appears that the T5+ (T 1+,T 3+,T 5+) T-cell is
+
+
+ + +
analogous to the Ly-~3 T-cells, and the T4 (T 1 ,T 3 ,T 4 )
T-cell is analogous to the Ly-1+ found in mice. Therefore,
like other cell surface molecules (e.g. immunoglobulins,

6

7

LEGEND
(See Benacerraf)

Figure 1.

Genetic Map of the Major Histocompatibility Complex
in Mouse (H-2 Complex)
The H-2 Complex found on mouse chromosome 17
consists of 5 regions: K,I,S,G, and D. The K and D
regions contain the H-2K and H-2D marker loci which
determine cell membrane antigens expressed on almost
all tissues. The K and D gene products function as
the major histocompatibility a~tigens. They can
stimulate cytolytic responses by T-cells and antibody
responses by B lymphocytes. The S region contains
the Ss locus which controls components of the
complement system. The G region contains the H-2G
locus which controls an erythrocyte alloantigen which
has not been associated with any biological function.
The I region is divided into 5 subregions: I-A, I-B,
I-C, I-E, and I-J. Ir genes which control the ability
to develop specific immune responses to thymus-dependent antigens are found in the I region. In addition,
a new class of alloantigens, Ia antigens are coded for
by the I region. Ia antigens are selectively expressed
on B lymphocytes and macrophages.
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and the major histocompatibility complex encoded ant]gens}, the
antigens defining the phenotypes of inducer and suppressor/cytotoxic
populations have been conserved, at least in mouse, rat, and man,
and probably throughout the entire mammalian family.
Subpopulations of T-cells can also be differentiated on the
basis of their Fe (36} receptors of immunoglobulins (37}.
types ofT-cells have been identified:

T~-cells

Four

contain an Fe

receptor on its cell surface for IgM; Ty-cells a Fe receptor for
IgG; Ta-cells a Fe receptor for IgA, and T£-cells a receptor IgE.
These cells are identified and purified by a resulting technique
using Ox

RBC-Ig~

for

T~-cells,

Ox RBC-IgG

forTy-cell~,

Ox RBC-

TNP-IgA for Ta-cells, and Ox RBC-IgE for TG-cells (38,39}.

It

should be mentioned that these receptors ·are also present on
B-cells (37}.

Studies with different mitogens have shown

T~-cells

function as helper cells, while Ty-cells function as suppressor
cells (38-42}.

The precise roles of Ta-cells and T£-cells as of

yet remain to be elucidated; however, T -cells may regulate the
specific IgA response of B lymphocytes (37,43}.
T lymphocytes may also be differentiated on the basis
of receptors for histamine (38}.

When purified T lymphocytes

from peripheral blood was passed over a histamine-coated
sepharose column (44}, approximately fifty-percent ofT -cells

were retained by the column and all the
through the column.

T~-cells

passed

Thus, it appears two populations of

Ty-cells (Histamine + and histamine-) exist; and

T~

cells lack histamine receptors.
T lymphocytes also show differentiated sensitivities
to radioactivity (38,45-.49), corticosteroids (38,50),
thymic humoral factor (51), and their responsiveness to
the mitogens phytohemagglutinin and concanavalin A (52).
Ty (Ly-2,3+ in mouse) suppressor/cytotoxic cells have been
shown to be sensitive to low dose (500-1000 rads)
irradiation~ vitro, while T~ (Ly-1+ in mouse) helper cells

are resistant to such dosages (49).

~·

Segal et

(50) have

shown that pretreatment of mice with hydrocortisone caused
an inhibition ofT-cell function in humoral immunity, while
enhancing the graft-versus-host reactivity.

Thus, it

appears that helper cells are sensitive to corticosteroids,
while cytotoxic activity is enhanced.
Fauci et

~·

On the other hand,

(53) has shown that hydrocortisone enhances

the generation of antibody-secreting

cells~

vitro;

however it is believed that the enhancement was the result
of the inhibition of suppressor cells.
Finally, Knapp and Posch (54) found non-activated
suppressor T-cells appear to be sensitive to hydrocortisone,
whereas activated suppressor cells seem not to be.

In

addition, they showed that hydrocortisone could enhance or
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diminish suppressor cell activity depending on the concentration
used and the time at which the hydrocortisone was added.
Table 2 (37) summarizes some of the differences between helper
(T~)T-cells

and suppressor/cytotoxic (Ty)T-cells.

While the evidence supports the existence of subclasses
ofT-cells, the question arises as to whether the subclasses
exist prior to activation by antigen or mitogen.
Boyse (26) found that mouse T-cell subclasses Ly-1

Cantor and
+

and Ly-2,3

+

separated prior to antigenic stimulation, express exclusively
helper or cytotoxic function. Jandanski and his coworkers (25)
have shown that while Ly-1 + and Ly-2,3 + T-cells are equally
activated by con A to incorporate [3HJ-thymidine, Ly-1+ T-cells
elicit helper responses, while Ly-2,3+ T-cells elicit suppressor
responses in the sheep red blood cell-plaque forming cell assay
(55,56); moreover the same results could be obtained even if
the two T-cell types were separated prior to con A stimulation.
Finally, Reinhera and his coworkers (33,35) have shown that
while T4+- and T5+- cell subpopulations are equally activated
by mitogenic stimulation to proliferate, only the T5+-cell
population became suppressive.

Therefore, in addition to

existing as distinct subclasses, the nature of the T-cell
appears to be established prior to activation by antigens or
mitogens.

TABLE 2

12
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CHARACTERISTICS OF HUMAN T CELL SUBPOPULATIONS

Characteristics:
B-cell differentiation
T-cell proliferation
Natural killer activity
Antibody-dependent
cytotoxicity ·
Blastogenic responses to
Phytohemagglutinin
Concanavalin A
Allogenic cells
Mediator production
Migration Inhibition
Factor(LMIF)
Interferon
Adherence to nylon wool
or glass
Electrophoretic mobility
Locomotor properties
Ia antigen
Histamine receptors
Thymopoietin ·
Sensitivity to
Corticosteroids
Irradiation
Pronase
Trypsin
Neuramidase _
RNA content
Morphology
Cytoplasmic/Nuclear
ratio
Golgi body
Rough endopiasmic
reticulum
Cytoplasmiclgranules
Alpha-nep~thyl __ a.c~~a~e
esterase.

Tll.Cells

Ty .Cells

ts

-ts
-ts
+S

?

+S

+

+

+

+

+

+
+

+

High

tow

+S

+

+
+S
t

+

+
+

+
+
+

High

Low

I

Low
Few
Scanty

High
Rich
Abundant

+

+ Granular

Symbols: S • subpopulation, t = enhancement,
+ • positive, and - = negative

~

= inhibition
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Suppressor T-cells
The first information concerning suppressor T lymphocyte

activity was provided by Gershon and Hondo (58) of Yale in 1970.
In their paper they described experiments which showed that a
state of non-responsiveness to a particular antigen could be
transferred to an animal which had been previously responsive to
that antigen.

In their experiment, lymphocytes from mice made

tolerant to sheep RBCs were adoptively transferred into mice
capable of responding to sheep red blood cells (SRBCs).

The

recipient mice were then found to be non-responsive to SRBCs.
Since then, suppressor T-cells have been shown to play a
role in a number of humoral (58) and cell-mediated processes
(16,20,57-63).

In addition, suppressor T-cells have been shown

to be involved in the etiology and pathogenesis of a number of
disease states such as Hodgkin's disease (64), multiple sclerosis
(65), systemic lupus erythematosus (66,67), inflammatory bowel
disease (68), allergies (69), common variable hypogammaglobulinemia
(70), aging (71), and renal allograft rejection (72,73).
Experiments with the antimetabolite cyclophosphamide (29),
show that two types of suppressor T-cells exist.

The

11

initiator 11

suppressor T-cell is sensitive to cyclophosphamide, while the
11

effector 11 suppressor T-cell is resistant to cyclophosphamide.

Upon antigen or mitogen stimulation, the initiator suppressor Tcell is activated to produce a soluble suppressor factor which

14

then activates the effector suppressor T-cell.

The effector T-

cell then carries out suppressive actions on T-cell to T-cell
and T-cell to B-cell interactions.
IA-4.

Mechanism ofT-cell Suppression
The mechanism by which suppression T-cells inhibit the

various humoral and cell-mediated responses remains largely
unknown.

However, it appears that the inhibition of cellular

proliferation may represent a common pathway by which a variety
of suppressor T-cells regulate both humoral and cell-mediated
immune responses.

It can be demonstrated that suppressor T-

cells induced by either antigenic (57,76) or mitogenic
stimulation (22) are both capable of suppressing proliferative
B-cell responses and antibody formation (74).

Moreover,

suppressor T-cell populations have been shown to suppress Tcell proliferation and the development of cytotoxic T-cells in
mixed lymphocyte culture (20,63,76,77).
Another manner in which suppressor T-cells act is by
interferring with cell to cell interactions between T-cells or
between macrophages and T-cells.

Ferguson et

~·

(125) have

shown that murine spleen cells cultured in the presence of
heterologous serum suppressed normal spleen cells from
responding in a cell-mediated

cytotoxicity (CMC) assay.

addition, suppression was shown to be exerted on some early
phase of cell-mediated cytotoxicity generation.

In

Besides the mode of suppression, another facet of suppression
which must be addressed is that of the target ofT-cell suppression.
In the case of suppression of humoral immune responses, i.e. immune
phenomena involving the production of specific antibody, the
immediate target could be a specific helper T-cell, a macrophage, or
even the B-cell (79,80).
Tada and his co-workers (74) have presented evidence that
the immediate target of suppressor T-cells are specific helper
cells.

By transferring lymphoid cells (spleen and thymus) from

rats immunized against a specific hapter-carrier conjugate (e.g.,
dinitrophenol (DNP)- Ascaris or DNP - Bovine Serum Albumin (BSA))
into syngenic rats, i.e. rats inbred until homozygous for all gene
loci, producing the antibody IgE, they were able to show
suppression to be dependent on helper T-cells which carried
specific determinants for the carrier molecule.
Another possible target of suppressor T-cells is the B-cell.
Baker (81) was able-to show the inhibitor of antibody responses
by suppressor T-cells interacting directly with a B-cell membrane
determinant.

Additional evidence which points to the S-cell as

being the immediate target of suppression comes from the work of
Pierce and his co-workers (75).

They showed that T-cells from

patients suffering from hypogammaglobinemia suppressed the
immunoglobulin synthesis by normal B-cells, presumably by acting
directly on the B-cells or on macrophages.

Figure 2 depicts

three possible models for T-cell regulation of B-cell responses.
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Figure

a.

Possible models for T cell regulation of B
cell responses: (a) The same T cell gives 'on
and off' signals to B cell, in which 'too much
help' ,would become inhibitory; (b) two
differnt types of T cells(helper and suppressor) give differnt signals to B cell; (c)
Helper T cell sends 'on' signal to both Bs
(sensitive B) cell and the suppressor T cell.
A sufficient number of suppressor T cells
thus generated would in turn suppress both
helper T cell and sensitive Bs cell, The
response of insensitive(T cell-independent)
Bi cell are not affected.
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Evidence that the macrophage is the immediate target of
suppressor T-cell actions comes from the work of Basten et
{82).

~·

Leukocytes made tolerant to human gammaglobulin (HGG)

were treated with anti-thy serum and complement, or passed through
an anti-immunoglobulin coated column to obtain purified tolerant
T-cells.
mouse.

Thy-1 or theta is an antigen found on T-cells in the
When the HGG-tolerant T-cells were injected into irradiated

hosts they failed to inhibit the anti-DNP response.

However, when

the HGG-tolerant T-cells were injected along with a second
population of cells possessing adherent properties, suppression
of the anti-DNP response was completely restored.

Since it

appeared that the second cell population was probably not comprised
ofT-cells, but rather

~cells

or macrophages, the tolerant cells

were passed through a column coated with an irrelevant antibody
(e.g., anti-sheep red blood cell antibody).

Immuno-fluorescent

staining with anti-immunoglobulin confirmed normal number of
B-cells were present in effluent.

When the cells obtained from

the effluent were transferred into irradiated hosts, minimal
suppression of the anti-DNP response occurred.

Apparently, the

column removed the adherent cells, which were most likely
macrophages.

Confirmatory evidence that this was the case was

obtained by passing tolerant spleen cells through a glass wood
column which retains macrophages.
As is the case with humoral responses, various T-cell and
non-T-cells (e.g., B-cells and macrophages) appear to be targets
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of cell-mediated suppression.

Gershon and co-workers (83) have

shown that T-cell mediated processes such as graft-versus-host
rejection (GVHR) were repressed or inhibited by the direct action
of suppressor T-cells on other T-cells.

Several studies of the

mechanism of suppression of cytotoxic T-cells indicate that
suppression is mediated by both T-cells and non-T-cells (84-87}.
~·

Rode et

(88) have proposed two mechanisms by which suppressor

T-cells inhibit cytotoxic lymphocyte activity in humans:

The

first involves the suppressor cell binding to, or in some manner
preventing helper T-cells from mediating cytotoxic activity.

The

second mechanism suggests that suppressor T-cells abrogate cytotoxic
T-cell activity by inhibiting precursors of cytotoxic T-cells.
Kimple and Henney (89) have presented evidence which
suggests that suppressor T-cells act on macrophages, which in turn
prevent cytotoxic T-cell activity by preventing cytotoxic T-cell
precursors from differentiating via DNA-independent mechanisms.
The final factor to be considered involves the manner in
which suppressor T-cells transmit their effect; that is, either
by direct contact with their target or by the elaboration of
suppressor factors which then suppress the intended target.

A

number of suppressor factors secreted by activated suppressor
T-cells have been identified (15,74,76,90).
Tada and his co-workers (74} have isolated two suppressor
factors.

One is a small membrane-sound protein from spleen

cells which is capable of suppressing IgE-synthesis.

The other

20

suppresses the IgG response to Keyhole Limpet Hemocyanin (KLH), a strong
thymus-dependent antigen often used in hapten-carrier conjugates.
Benaceraff and his co-workers {76) have identified an antigen-specific
suppressor T-cell factor which appears to be involved in the genetic
control of the specific immune response to the polypeptide gly-alatyrosine.
Suppressive factors which suppress cell-mediated processes have
also been identified.

Zembala et

~·

(15) have isolated a T-cell

suppressor factor which is capable of depressing the passive transfer
of contact sensitivity of mice to picryl chloride (PCl), which had been
applied to their skin after pretreatment with picryl sulphonic acid
(PSA).

In contrast to the factor described by Tada and others, this

factor was released into the media from cultured primed lymph nodes.
Finally, Truitt and co-workers (87) have identified two different
suppressor factors.

One, MLR-TSF has been shown to suppress lymphocytes

from undergoing blast formation {proliferation) in mixed leukocyte
culture reactions.

The second, CTL-TSF suppresses the generation of

cytotoxic lymphocytes in mixed leukocyte cultures.
While additional work is needed to elucidate the mechanism(s)
of T-cell suppression, it appears that various cell-mediated and
humoral mediated responses are regulated by a number of different
suppressor pathways.

In addition to suppressor T-cells, other T-cell

and non-T-cells have been shown to play an important role in the
suppression of the many cell-mediated and homoral immune responses.

IA-5.

Role of Suppressor T-cells in Renal Allograft Rejection
Graft rejection usually follows transplantation of tissues

between unrelated individuals because of an immune response by the
recipient towards antigens expressed on cells within the graft (73).
Graft rejection (acute rejection) is considered to be largely a cellmediated immune response (90), although humoral immune responses also
play a role, and appear to be the main cause of hyperacute rejection
(91}.

Evidence supporting the contention that acute renal allograft

rejection is a cellular-mediated process comes from studies of
patients whom were treated with anti-thymus globulin (ATG), a known
patient inhibitor of cell-mediated immunity (90).
Because allograft rejection is looked at as largely a cellmediated phenomenon, various groups have looked into the role the
various subclasses ofT-cells play in the processes of rejection.
The role cytotoxic T-cells play in renal allograft rejection has
been fairly well characterized (92-94).

However, little is known

about the roles that helper T-cells and suppressor T-cells play (92).
Evidence that suppressor T-cells are involved in transplant
tolerance comes from experiments that are essentially extensions
of the early transfer of tolerance experiments of Argyris (95-96).
He showed that mice exposed to whole-body irradiation and then
innoculated with cells from tolerant donors became specifically
tolerant themselves.

Kilshaw and Brent (97) were able to demonstrate

suppression of the rejection of skin allografts when T-cells were
adoptively transferred from mice with intact long standing skin
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grafts to low dose irradiated syngenic recipients, although normal
cellular immunity was observed in vitro.
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Numerous other transfer

experiments (see review 73) have been done; however, the results of
these experiments to demonstrate suppressor T-lymphocytes in renal
allograft tolerant hosts by in vitro assays have been contradictory
and particularly difficult to relate to the in vivo situation.
Other types of experiments have demonstrated that suppressor
T-cells are probably involved in suppression of renal allograft
rejection.

Jayavant et

~·

(73) was able to show the existence of

suppressor cells in human renal allograft recipients.

They showed

that there was a significant correlation between a functioning,
nonrejecting allograft and the allograft recipient•s suppressor cell
activity.

Hendry et

~-

(98) showed that while suppressor cells were

present in the thymus of rats during the first week or so after
transplantation, they were unable to demonstrate their presence in
long-tenm kidney allograft recipients.

Liburd and his co-workers

{99-101) have shown the existence of donor-specific suppressor Tlymphocytes generated in vivo in renal allografted recipients, capable
of suppressing the in vitro generation of cytotoxic cells in normal
responders.

Thus, suppressor T lymphocytes appear to be involved

in the process of allograft tolerance.

However, their mechanism

of action still remains to be elucidated.

IA-6.
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Monitoring of Renal Allograft Rejection
The main problem that renal transplant patients face is

rejection of the donor graft.

In an effort to prevent rejection,

a number of immunosuppressive drugs (e.g. prednisone and
azathioprine) have been used.

While immunosuppressive therapy

has enjoyed some success in reversing rejection episodes, the
therapy remains ineffectual in about 50% of cadaver transplants
(102).

Furthermore, the use of immunosuppressants results in the

inappropriate suppression of the host's immune response, which
protects the recipient against infection, and is responsible for
about 60-70% of recipient deaths post transplant (102).

In an

effort to predict rejection crises and assist in evaluating the
efficacy in immunosuppression, a number of different approaches
have been undertaken.
The initial approach to predicting kidney graft rejection
depended on monitoring metabolic changes in peripheral blood
leukocytes.

Hersh et

Al·

(103) showed that DNA synthesis in

peripheral blood leukocytes increased at the time of rejection.
Page et

~-

(104) found that an increase in DNA synthesis by

peripheral blood lymphocytes was predictive of a rejection crisis.
In addition, the measurements of DNA synthesis (lymphocyte
blastogenesis) allowed for judging the adequacy of immunosuppressive
therapy for these crises.
Parker and Mowbray (105) showed the rate of RNA synthesis

increased during a rejection episode.

In addition,.this increase

in RNA synthesis was accompanied by a simultaneous increase in
the number of large, atypical mononuclear cells which appear to
resemble immature cells of the myeloid series.

Furthermore, they

showed that both the increase in RNA synthesis and the increase
in large, atypical monocytes occurred 8 to 9 days before rejection
was clinically evident.
Another method used to monitor renal allograft rejection
was measuring the blastogenic response of peripheral blood
lymphocytes subjected to either mitogenic {e.g. phytohemagglutinin)
or antigenic {donor or third party lymphocytes) stimulation.

When

phytohemagglutinin {PHA) is used, the assay is sometimes referred
to as "PHA escape".
Work by Thomas and his co-workers {106,107) have suggested
that the measurement of PHA-induced blastogenesis was a useful
technique for detecting a prerejection state, especially when
used in conjunction with measurements ofT-cell levels {107).
On the other hand, Page et

~-

{104) demonstrated that

monitoring lymphocyte responsiveness to phytohemagglutinin was of
no value in predicting rejection or in evaluating the efficacy
of immunosuppression.
Copeland et

~·

In accordance with these findings,

{108) showed the response of lymphocytes to

specific and non-specific mitogens proved to be neither useful
for predicting rejection nor as a guide to the adequacy of
immunosuppression.

Finally, Buckingham et

~-

{109) showed
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that the serial assessment of transplant recipients.using mitogenicallyinduced lymphocyte blastogenesis did not reliably predict rejection.
However, they found that protein synthesis, using the ratio of 16-hour
PHA-stimulated lymphocytes to non-stimulated lymphocytes, increased
prior to the onset of rejection.

Similar analysis of mitogen-induced

DNA-directed blastogenesis ratios revealed no significant difference.
A second approach to the monitoring of renal allograft rejection
involved measuring T-cell levels.

Thomas and his co-workers (106,107)

found that the most critical determinant of both accelerated and early
acute rejection was the level and reactivity of circulating thymusderived (T) lymphocytes.

Using a figure of 360 T-cells/cubic millimeter

or 20% of the normal circulating T-cell level, Thomas and his co-workers
(107} found that over 80% of recipients demonstrating acute rejection
had T-cell levels above 20% of normal.

In contrast, a majority of

patients not experiencing acute rejection in the first posttransplant
month had T-cell levels below 20% of normal.
significant at P less than 0.05.

These differences were

In addition, the mean time of

appearance of elevated T-cell levels (above 20%) prior to the onset of
clinically apparent rejection was 5.9 days.

Buckingham et

2l· (109)

also found T-cell levels to be indicative of acute rejection.

In

contrast to the other groups, they found that rejection takes place
in an environment of decreased numbers ofT- and B-lymphocytes as
compared with normally observed levels.
Finally, Kerman and Geis (110,111) found immunologic monitoring
of a subpopulation of peripheral blood T-cells known as the active
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T-rosette forming cells (active T-RFC) represent an.effective method
for defining and predicting rejection episodes.

In addition, they

suggested that monitoring active T-RFC levels might be beneficial
in accessing the effectiveness of daily antithymocyte globulin (ATG)
dosages, as well as delineating other interventions which alter the
recipients' peripheral T-cell level.

When an allograft recipient

experienced a clinical rejection episode, a decline in the percent of
active T-RFC occurred.

Therefore, it has been suggested that the

active T-RFC represents an "immunocompetent" cell (ll2-114), capable
of recognizing and attacking the allograft; thus, explaining its ,
decline durign a rejection episode.
Humoral and cellular-mediated immune responses play a decisive
role in the acceptance or rejection of allogenic grafts (115).

In

clinical transplantation of kidneys, both hyperacute and chronic
rejection appear to result from circulatory antibodies whereas acute
rejection episodes appear to be due to the
mediated immune responses (116).

a~tivation

of cell-

Thus, the final approach used to

monitor kidney post-transplant patients involved tests which measured
the immunologic responses of the graft recipient to specific antigens
of the graft donor.
Cell-mediated lymphocytotoxicity is a measure of recipient's
effector cells, i.e. cytotoxic T-cells, null cells, or macrophages
to lyse target cells, i.e. PHA-activated lymphocytes obtained from
the spleens of cadaver donors or from the peripheral blood of a
single donor, labeled with chromium-51.

Stiller et

~-

(116) found

cell mediated lymphocytotoxicity (CML) to be highly predictive of
rejection episodes.
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They obtained positive CML responses for 41 of the

45 patients experiencing rejection episodes; whereas only 4 of 29
patients demonstrated positive CML during periods of clinical quiescence.
In addition, they showed that the ability of the test to predict a
rejection episode was independent of when the test was carried out.
Statistically comparable results were obtained whether the test was
carried out one day, one week, or two weeks prior to the onset of
clinical rejection.

Thomas and his associates (117) found a high

correlation between negative CML (specific CML unresponsiveness) and
graft survival.

In addition to enhanced survival, they found that 50%

of the patients (5 of 10 patients) exhibited a significant suppressive
effect on third-party to donor cell-mediated lymphocytotoxic responses.
The role of suppressor cells in the regulation ofT-cell mediated immune
reactions (e.g. suppressor T-cell inhibition of cytotoxic T-cell
responses) have been previously reviewed (Sections IA 3-5) and will be
further discussed in the Results and Discussion Sections.
Another test which has been used to monitor renal allograft
rejection is direct lymphocyte mediated cytotoxicity (LMC).

Direct

LMC is an in vitro test of cell-mediated immunity which reflects
in vivo sensitivity toward a specific antigen.

In addition, LMC is a

thymus-dependent, non-complement-requiring process in which close cellto-cell contract is a prerequisite (118).

While there appears to be a

good correlation between CML activity and chronic renal rejection
(118,119), LMC has proved to be an invaluable prognosticator of acute
rejection, especially in patients treated with antilymphocyte globulin

28

(ALG)(l07,119,120).
A third specific anti-donor test which has been used to
measure both acute and chronic rejection is antibody-dependent cellular
cytotoxicity (ADCC).

Antibody-dependent cellular cytotoxicity is a form

of lymphocyte-mediated cytotoxicity in which an effector cell kills an
antibody-coated target cell (e.g. lymphoblast or tumor cell), presumably
by recognition of the Fe region (121) of the cell-bound antibody through
an Fe receptor present on the effector lymphocyte (122).
of ADCC is depicted in Figure 3.

The mechanism

Unlike CML and LMC where the main

effector cell is the cytotoxic T-cell, the main effector cell in ADCC
appears to be a "null" or K lymphocyte (122).
Thomas and his co-workers (101) found that anti-donor ADCC was
associated with early acute renal rejection if present pretransplant or
in the first two post-transplant weeks.

On the other hand, ADCC which

developed after the first two post-transplant weeks was found not to be
indicative of acute rejection.

In an earlier study, Thomas and his

associates (123) showed that a positive correlation existed between
chronic renal allograft rejection and ADCC activity.

In the study,

seven out of the seven patients, 1 to 10 years post-transplant,
exhibiting clinical symptoms, i.e. persistent proteinucia greater
than 1 gram per 24 hours, of chronic rejection, displayed positive
ADCC values, whereas, 11 out of the 13 (85%) patients (2 to 11 years
post-transplant) not showing clinical symptoms of chronic renal
allograft rejection had negative ADCC values.

Recent studies

(120,124) have also shown that monitoring ADCC activity to have
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Figure 3:

The process of antibody-dependent cell mediated cytotoxicity (ADCC) is illustrated. Specific antibody,
secreted by plasma cells, binds to cell surface antigens
on the tumor cell. "Null: or K cells possessing Fe
receptor bind to the Fe portiop of these cell associated
antibodies, and kill the attached tumor cells.
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prognostic value for acute allograft rejection.

The final two methods used to monitor renal allograft rejection
involved measuring the amount of lymphocyte-dependent antibody {LOA)
activity or complement-dependent antibody {COA) activity.

Thomas and

his co-workers (119) found a strong correlation between LOA activity
and chronic, renal rejection.

Ninety-three percent of LOA-positive

patients had a clinical course characteristic of chronic rejection,
whereas 92% o'f LOA-negative patients demonstrated good rena 1 function,
i.e. renal function as defined by creatinine, creatinine clearance,
and urine protein.

On the other hand, Stiller et

~·

{116) showed

that there was no statistical difference for LOA activity between
patients experiencing rejection episodes or patients without rejection
episodes.
With regards to the complement-dependent antibody test,
Stiller et

~

{116) show that there was a clear association between

COA activity and rejection.

Of 15 rejection episodes, COA was positive

in 12, and on no occasion was COA activity positive during a period of
quiescence.
lB.

The various tests are summarized in Table 3.

Effects of Splenectomy, Pretransplant Transfusion and AntiGlobulin Administration in Renal Transplantation

IB-1.

Effect of Splenectomy on Renal Allograft Survival
Splenectomy as an adjunct to kidney transplantation was first

suggested by Starzl and his co-workers {125,125) as a way of reducing
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TABLE 3
Summary of the Various Immune and Metabolic Tests to
Monitor Acute and Chronic Renal Rejection
Name of Test *

Type of Rejection Monitored

DNA/ RNA Synthesis

Acute

PHA or Con A Blastogenesis

Acute

T Cell Levels

Acute

Mixed Lymphocyte Culture

Acute

Tnymus-Dependent Rosette-Forming
Cells

Acute

Ce 11-Medi a ted Lymphocytotoxi city

Acute and Chronic

Lympnocyte-Mediated Cytotoxicity

Acute

Antibody-Dependent Cellular
Cytotoxicity

Acute and Chronic

Lymphocyte-Dependent Antibody

Chronic

Complement-Dependent Antibody

Acute

* Represents the various tests which are discussed
in the text.
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the total lymphoid mass, i.e. spleen and thymus, so as to diminish
allograft rejection.

In addition, they suggested that splenectomy

would also permit the use of larger doses of the immunosuppressant
azathiopine, a practice which would also contribute to the prevention
of rejection.
Subsequent studies on splenectomy as a therapeutic tool against
renal allograft rejection have been inconclusive.

Veith et

~·

(127)

were unable to demonstrate any beneficial effect of splenectomy in a
small series of canine and human homotransplants.

Bennett et

~-

(128)

reported that pretransplant splenectomy did not decrease the number of
rejection episodes per month of graft function, and were associated
with a higher rate of septic, i.e. systemic disease caused by the
presence of microorganisms or their toxins in the circulatory blood,
and thromboembolic, i.e. embolism from a clot dislodged from a vein,
complications.

Opelz and Terasaki (129) in a study of 1653 renal

transplant patients obtained- from 51 transplant centers, were unable
to demonstrate any beneficial effect of splenectomy.
Rai et

~·

More recently,

(130) carried out a retrospective study of 199 patients who

had received a kidney transplant between January, 1968 and June, 1974.
They found that there was no significant difference in graft loss
between patients who had undergone splenectomy, and those which did
not (control group).

In addition they showed that splenectomy did not

reduce leukopenia, i.e. reduction below 5000 per cubic millimeter in
the total number of leukocytes in the circulatory blood, so as to
permit the use of larger doses of azathioprine.

Finally, the group
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which had a splenectomy experienced a higher mortality rate, largely
due to an increased susceptibility to infection.
While the preceding studies contra-indicate splenectomy as
a therapeutic adjunct to transplantation, other studies reported
improved graft survival.

Kauffman et

~·

(131) found a much lower

rejection rate in forty recipients splenectomized prior to transplantation than in twenty-three patients splenectomized after transplantation
or in the thirty-one patients who retained their spleen throughout
the test.

In addition,

they found that the white blood cell count

of patients who had a pretransplant splenectomy was significantly
higher at day thirty postoperatively, than the white blood cell
counts of patients who had a splenectomy after transplantation, or
not at all.

Moreover, this increase in white blood cells permited

the more effective use of immunosuppressive drugs.
IB-2.

Therapeutic Enhneement of Renal Allograft Survival With
Pretransplant Transfusion
Prior to the finding of Opelz and Terasaki (132) that the

administration of blood transfusions to dialysis patients awaiting
transplantation was associated with improved graft survival, it had been
the practice of transplant services to minimize transfusion prior to
transplantation to avoid presensitisation and fromation of cytotoxic
antibodies.

Since then, numerous retrospective studies have confirmed

that pretransplant transfusion improved renal allograft survival for
cadaveric kidney recipients (133-137).

Finally, the U.S. Registry

which deals with the results obtained from the majority of American

35
centers estimated in its final report of 1977 that the average effect
of transfusion on one-year survival of cadaver kidney grafts was 44%
without compared to approximately 60% with transfusions (138).

While a

majority of the studies on cadaver kidney recipients indicate a positive
effect for pretransplant transfusions, two groups, Jeffery and his
co-workers (139,140) and Sengar et

~·

(141) failed to demonstrate graft

prolongation due to pretransplant transfusions.

However, their failure

to demonstrate positive effects on one-year graft survival due to
pretransplant transfusions could be attributed to the extremely high
survival rate of the non-transfused recipients (71% for Jeffery's group
and 75% for Sengar's group).
A second area which has not been as exhaustively studied as the
preceding one, is the effect of pretransplant transfusion or graft
survival in living related recipients.

Patients that received kidney

transplants from living-related donors may, from an immunological point
of view, be divided into two rather homogenous groups: those that
received HLA (histocompatibility antigens in humans) - identical grafts,
and those receiving one halotype (inheritable antigens or genes from
one parent) mismatched ones.

In a study of 191 consecutive living

related transplant patients, Solheim and co-workers (142) found that
transfusions enhanced graft survival for transplant patients with one
HLA halotype - disparabe kidney, whereas transfusions had no effect
on the survival of HLA-identical transplants.

In addition, the

frequency of first rejection episodes was significantly reduced in
transfused compared to non-transfused one halotype-mismatched

transplants, while no influence of blood transfusions was seen
in patients with HLA-identical transplants.
Three additional factors which have been investigated
are the effect of timing, number and the nature of transfusions
on graft survival.

Stiller et

~·

(143) observed that transfusion

given on the day of transplantation were effective in increasing
graft survival.

Hunsicker et

~·

(144) found that transfusions

given on the day of transplantation were statistically as
effective as transfusion administered prior to transplantation
Finally, Freeman et 2.]_. (145) provided data which

(Figure 4).

indicated that preoperative transfusions, i.e. blood given during
the operation, contributed to graft survival.
Studies on the effect of administ"ering multiple transfusions
suggested that multiple transfusions enhanced graft survival.
Hunsicker et

~·

(144) showed that maximum graft enhancement at

three months could be achieved with as few as 3 units of blood.
Opelz and his co-workers (146) demonstrated that graft survival
corresponded to the number of blood units transfused, with maximum
survival rates occurring at greater than 20 units of blood
transfused.

While the majority of studies confirm the enhancing

effect of multiple blood transfusion on renal allograft survival,
Van Rood et

~·

(147) found no correlation between the number of

transfusions and ultimate survival.
The blood administered in transfusions can be of several
types: Whole blood, red blood cells only, washed cells (leukocyte
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poor}, plasma, or packed red blood cells (148).

Hunsicker et al.

found there was no significant difference in graft survival between
patients receiving only frozen erythrocytes and those receiving
only leukocyte poor packed erythrocytes (77% and 81%, respectively).
Briggs et

~·

(149} obtained results which showed no significant

difference in graft survival between patients receiving frozenthawed red cells or whole blood (29% and 23%, respectively).

Opelz

and Terasaki (149) had earlier demonstrated that frozen blood was
somewhat less effective than packed cells or whole blood in
producing a beneficial effect on transplant outcome.
IB-3.

Effect of Anti-Thymocyte Globulin Administration on Renal
Allograft Rejection
The most common method currently used to treat acute

rejection of renal allografts is to temporarily increase the dose
of corticosteroids.

Unfortunately, protocols utilizing oral

administration of divided doses of steroids are not always
successful in reversing rejection, and are frequently associated
with side-effects and long-term complications.

In an attempt to

avoid some of the toxic effects of high-dose corticosteroid
treatment, many physicians have turned to the intermittent
intravenous administration of Solu-Medrol (methyl predisolone)
for reversing rejection.

While Solu-Medrol has been reported

to have been effective in reversing rejection (151,152),
widespread usage appears to be associated with definite risks,
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e.g. unexpected cardiac arrhytMlias, infection, and gastrointestinal
hemorrhage.

With this in mind, several transplant groups have

turned to the use of anti-thymocyte globulin (ATG), either as an
adjunct or in place of high dose steroids.
The immunosuppressant ATG represents the globulin fraction
of antilymphocyte serum (ALS).

It is prepared by injecting T, B,

or mixtures ofT and B-cells from humans into horses, and isolating
the globulin fraction of the resultant horse anti-serum.
Early studies on animals showed that antilymphocyte
globulin (ALG) had a positive immunosuppressive effect in a
majority of the experiments.

The first clinical studies on humans

were carried out by Starzl and his co-workers (153).

Using

living-related donors with good histocompatibility, they found
that when ALG was given 5 days before transplantation and continued
for 4 months, kidney .survival rates improved.

In addition, steroid

doses were cut in half, and azathioprine doses were reduced.

On

withdrawal of ALG from patients who had received kidneys from
non-related cadaveric donors with poor histocompatibility,
Starzl et

~·

noted a progressive deterioration in the graft.

Commenting on Starzl 's work, Van Rood (154) noted that ALG permitted
the reduction of steroids in cases where there was a good match
for histocompatibility antigens, but could not override the strong
histocompatibility differences in the group of non-related donors.
Since then, Starzl and his co-workers (155) have attempted to
prevent late rejection in homografts with histocompatibility
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differences by increasing the dosage of ALG, but their efforts have
been limited by the manifestation of thrombocytopenia, and lymphopenia,
i.e. decreases in the patient's platelets and lymphocytes, respectively.
An additional study by Mee and Evans (156) of patients who had received
a cadaver kidney with at least two major antigens mismatched, showed
that the patients who had received antilymphocytic serum (ALS) or
antilymphocyte globulin (ALG) in addition to steroids and azathioprine,
demonstrated survival rates that were no better than patients receiving
only steroids and azathioprine.
Controlled, randomized studies by Shiel et
Taylor et

~·

~·

(157) and

(158) showed that recipients of related and cadaver

kidneys who were treated with ALG had improved kidney and patient
survival when compared with the non-ALG treated (control) patients.
Contradictory results have been obtained by Howard et

~·

(159).

In

a randomized, double-blind study of renal transplant patients treated
with ALGor human IgG (control) in conjunction with the standard
immunosuppressive therapy, they found that the number of patients
requiring transplant nephrectomy, i.e. removal of kidney(s), and/or
dialysis, having good late function, or dying did not differ in
recipients of either living-related or cadaver kidneys; and only
recipients of cadaver kidneys showed significantly fewer second
rejection episodes.

Similar results were also obtained by Birtch et

(160) and Turcott et

~·

~·

(161 ,162), who were unable to demonstrate any

significant benefit of either ALGor antithymocyte globulin (ATG)
administered in the posttransplant period.
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While the studies on the benefits of ALG and ATG treatment
have been inconclusive, this may have been due to the fact that these
two immunosuppressants were only used as adjuncts to the conventional
rejection therapy.

In an effort to evaluate the effectiveness of ATG

alone, a prospective, randomized study was undertaken by Shield et
(163).

~·

Patients were initially treated with azathioprine and prednisone.

With the onset of acute rejection, patients were randomly assigned
additional treatment with either ATG or high-dose steroids.

Eight of

the ten patients treated with ATG had prompt reversal of acute rejection.
The other two patients required high-dose steroids, with only one of
the two patients regaining normal renal function.

On the other hand,

all of the patients treated with high-dose steroids experienced
initial reversal of rejection.

However, four required irradiation of

the graft and actinomycin therapy; and, five of the other six experienced
subsequent, second and third rejection episodes.

A follow-up study

(Mean post-transplant time of fourteen months) revealed that 9 of the
patients treated with ATG had functional grafts, with 8 of the 9
showing normal renal function.

On the other hand, 9 of the 10 patients

treated with high-dose steroids retained their grafts, but renal
function remained impaired in three.

IC.
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Goals of this Thesis
The major obstacle facing the renal transplant patient

is rejection of the donor organ.

While a considerable amount

of progress has been made in both the recognition of pre-clinical
rejection and the treatment of rejection, a large percentage of
renal transplant patients are subject to acute rejection from
ineffective immunosuppression,

Furthermore, this therapy can

result in the inappropriate suppression of the recipient's immune
system, leaving them vulnerable to infection.
Therefore, there is a need for a test which will allow
for the early prediction of impending rejection so that effective
treatment can be carried out.

In addition, the test must also

allow for the more accurate accessment of the effects of
immunosuppressive therapy.
Secondly, it is the intention of this thesis to determine
the effect of con A-pretreated peripheral blood lymphocytes
(suppressor T-cells) from renal transplant patients on the
blastogenesis of allogenic lymphocytes (resonder T-cells) isolated
from a single, healthy volunteer.
Finally, we plan to determine how pretransplant splenectomy,
pretransplant transfusion, and anti-thymocyte globulin administration
contributes to graft survival by analyzing the available data with
respect to kidney function values, i.e. creatinine, BUN, and
creatinine clearance, and serological values such as the total
lymphocyte number, T-cell and B-cell number.

CHAPTER II
MATERIALS AND METHODS
IIA.

General Materials and Sources
Peripheral lymphocytes were obtained by consent from renal

transplant and renal dialysis patients, and from healthy, adult
volunteers at both Foster G. McGaw Hospital, Maywood, Illinois, and
Hines Veterans Administration Hospital, Hines, Illinois.
Culture media used in the experiments consisted of RPMI 1640
(without antibiotics) supplemented with Hepes buffer solution (25 mM),
Penicill.in/Streptomycin (10,000 units per ml and 10,000 meg per ml,
respectively),

L-Glutamine (20 mM) and heat inactivated fetal calf

serum (10% v/v).

All of the components of the culture media were

purchased from Grand Island Biological Company.
DNA inhibitor Mitomycin C was purchased from Aldrich Chemical
Company.

A stock solution (1.0 mg per ml sterile saline, 0.85% w/v)

was made and frozen until the day of the experiment.

On the day of

the experiment, the Mitomycin C solution is diluted to 50

~g

per ml

in Heper buffered (25 mM) RPM! 1640.
Concanavalin A (Grade IV) and Phytohemagglutinin-P were
t

purchased from Sigma Chemical Company, and Defeo Laboratories,
respectively.

These two plant mitogens were made up to the desired

concentrations in sterile saline, 0.85% w/v, and then frozen in
1.0 ml or 5.0 ml aliquots until needed.
42
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Lymphoprep, a ficoll-hypaque density gradient mixture was
purchased from the Accurate Chemical and Scientific Corporation.
Tritiated-methyl thymidine (2.0 ci/mmol) and Econofluor, a
zylene-based scintillation fluor were purchased from New England
Nuclear.
in the

Other materials used throughout the study will be mentioned

"~lethods

Section."

liB.

Methods

IIB-1.

Isolation of Peripheral Blood Lymphocytes
Peripheral blood lymphocytes were separated from fresh

heparinized (14.4 units per ml) blood from renal transplant and renal
dialysis patients, and from healthy, adult volunteers by Ficoll-hypaque
density gradient centrifugation using a modification of the technique
of Boytim (164).

Briefly, 20 to 30 cc (6-8 cc per tissue culture tube)

of whole blood was layered over 3.0 ml of Lymphoprep (specific density
1.077 g per ml) in tissue culture tubes (Falcon 3033), and centrifuged

for 30 minutes at room temperature at 1400

RP~1

(400 x gravity).

After

centrifugation, the top layer containing serum was carefully pipetted
off up to the the white cell band (Figure 4).

The white cell band

which contains predorni natly lymphocytes was then removed vJi th a Pasteur
pipet and placed in a clean tissue culture tube.

The cells were then

washed once in Hepes buffered (25 mt1)-RPHI 1640 by centrifugation at
200 x gravity for 10 minutes and then they were counted.

A Wright

stain differential of the solution was carried out, and the cells were
6

then diluted to a fi na 1 concentration of 1. 0 x 10 lymphocytes
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Figure 4. Separation of whole heparinized blood on a
ficoll-hypaque density gradient
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per ml of culture media.
IIB~2.

Determination of Lymphocyte Blastogenesis for Transplant
Patients and Normal Adults Versus the Concentration of
Concanavalin A.
In order to determine the concentration of concanavalin A

(con A) needed to elicit the greatest bastogenic response (recorded
as counts per minute), a series of experiments were carried out
using lymphocytes obtained from the peripheral blood of renal
transplant patients or healthy, adult volunteers, as described in
the preceeding section (Section II-Bl).

To a series of micro titer

wells lFalcon 3040}, 0.1 ml of the appropriate concentration of
con A dissolved in Hepes buffered RPMI 1640, was added to a 0.1 ml
patient or donor lymphocyte solution (1 x 106 lymphocytes/ml),
bringing the final concentration of the mixture to 0.2 ml per well.
Six determinations were C?rried out for each of the seven different
concentrations of con A tested.

The cells were then incubated for

sixty-four hours at 37°C in a humidified atmosphere of 5%

co2

(Liquid Carbonics}.

Eighteen hours before the termination of
incubation, 1.0 pCi of ( 3H-methyl)-thymidine (2.0 Ci/mM) were
added to each well.

The cells were then harvested on glass fiber

filter paper (Titertek Microtitration Equipment) using a multiple
cell culture harvester (Skatron).

The processed cells were allowed

to dry overnight and then counted in 10 ml of econofluor in a
refrigerated liquid scintillation counter (Searle Mark II LSC).
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Results were recorded as percent stimulation.
Percent Stimulation
Control
IIB-3.

=

Mean of individual count - control mean count
Mean of highest count

= 0 pg concanavalin A

Preparation of Suppressor T Lymphocytes
Peripheral lymphocytes isolated from renal transplant

patients and healthy, adult volunteers are resuspended to a
concentration of 1 x 106 lymphocytes per ml and split into two
groups.

The first group (suppressor T-cells) was incubated with

an equal volume of con A (5.0 pg per ml hepes buffered RPMI 1640)
in tissue culture multi-well plates (Linbro) in a humidified
atmosphere of 5%

co2

at 37°C for 44-48 ho~rs.

After the incubation

period, the cells were washed once, counted, and resuspended to a
concentration of 1 x 106 lymphocytes per ml culture media. The
cells were then incubated with an equal volume of Mitomycin C
(50 pg/ml) 106 lymphocytes) at 25°C for 45 minutes. The cells
werewashed twice and adjusted to a final concentration of 1 x 106
lymphocytes per ml.

The other group· of cells was prepared :in the

same manner as the first group except that it is incubated in the
absence of concanavalin A for the 44-48 hour incubation period.
This second group of lymphocytes then acted a! the control group.
IIB-4.

Preparation of Responder T Lymphocytes
Peripheral lymphocytes isolated from the same healthy,

adult volunteer as described earlier (see IIB-l),were adjusted

48

5

to a final concentration of 5 x 10 lymphocytes per ml culture media.
These cells then act as responder cells to which the concanavalin Aactivated and non-concanavalin A-activated (control) cells will be
added.
IIB-5.

Determination of Suppressor T-Cell Activity in Renal Transplant
Patients and Healthy, Adult Volunteers by Mitogen Stimulation
in Mixed Lymphocyte Culture
The suppressor assay is carried out in the following manner:

Lymphocytes were isolated from either transplant patients or healthy
adults as described in Section IIB-1.

To serve as an internal control,

100,000 responder lymphocytes (lymphocytes isolated from a single,
healthy adult) \'/ere added to the first two rov1s of the microtiter
plates (see Figure 5).

The next two rows consisted of 100,000

responder lymphocytes plus 50,000 ConA-activated suppressor lymphocytes.
The final two rows consisted of 100,000 responder lymphocytes plus
50,000 control lymphocytes {lymphocytes obtained from patients or
healthy adults which were not activated with Con A).

To the appropriate

well, either 10 ul of phytohemagglutinin-P (PHA-P)(100 ug/ml) or Con A
(50 ug/ml or 500 ug/ml) was added for stimualtion of the responder
lymphocytes.

The plates \>Jere then incubated for four days at 37°C in

a humidified environment of 5%

co 2 .

Eighteen hours prior to the
termination of the incubation period, 10 ul of ( 3H-methyl)-thymidine
(100 uCi/ml) were added to each well.

The cells were then harvested

on glass fiber filter paper, dried overnight, and counted in a liquid
scintillation counter.

Results are recorded as the percent suppression.
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Figure 5.

Example of Mixed Lymphocyte Culture:
Rows A and B contain 100,000 responder lymphocytes
per well.
Rows C and D contain 100,000 responder lymphocytes
and 50,000 Con A-activated suppressor lymphocytes
per well.
Rows E and F contain 100,000 responder lymphocytes
and 50,000 control lymphocytes per well.
Rows 1 and 2 are not mitogen stimulated.
Rows 3 and 4 are stimulated with 10 ul of PHA (100
ug/ml) per well.
Rows 5 and 6 are stimulated with 10 u1 of Con A
(50 ug/ml) per well.
Rows 7 and 8 are stimulated with 10 U11 of Con A
(500 ug/ml) per well.

N

u

50
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Suppressor Lymphs
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Suppression

IIB-6.

1 -

Non-Activated
Control Lymphs

-

Non Con A-Activated
Non-Stimulated
Lymphs
Non-Activated, Non
Stimulated Lymphs

X

100

Effects of Splenectomy, Transfusion, and ATG on
Acute Renal Allograft Rejection
A retrospective study of 51 renal transplant patients ( 1 week

to 7 years posttransplant) was undertaken to determine the effects of
splenectomy, transfusion, and antithymocyte globulin (ATG) on graft
acceptance.

Data was collected and arranged so as to allow for

the following comparisons of clinical values for:
1)

Patients experiencing acute rejection within one month
of testing versus patients who have not suffered a
rejection episode;

2)

Patients who on the test date had lymphocyte counts
above 6000 versus patients with lymphocyte counts below
6000.

3)

a)

Splenectomized patients versus non-splenectomized
patients.

b)

Transfused (pretransplant) patients versus
non-transfused (pretransplant) patients.

c)

Patients receiving ATG versus patients who have not
received ATG.

Data consist of both clinical test values as well as-immunological
factors,
(BUN),
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The clinical tests used were creatinine, blood urea nitrogen

and creatinine clearance values.

The immunological factors

consisted of white blood cell count, total lymphocyte numbers, i.e.
obtair1ed from whole blood or from Ficoll-hypaque gradient centrifugation,
T and C:-cell values, and the effects of splenectomy, pretransplant
transfusion, and ATG administration on graft survival and renal
function.
IIB-7.

Statistical Analysis of Data
Results of suppressor T-cells activity in both normals and

patients, differences between acute rejection and non-acute rejection
patients, and the various effects of sp 1e·nectomy, pretranspl ant
transfusion, and antithymocyte globulin administration on both renal
function and serological function were calculated and statistically
analyzed using the two sample, student's "t" test available through the
Minitab II (165) computer program.
Briefly, data for each experiment is entered into the
appropriate column, which corresponds to a particular group.

The

computer then calculates the following parameters:
m~l

= population means group

xlbar

= sample

mean group 1

Sl = sample deviation group 1
nl

= sample

size group 1

m~2

= population mean group 2

x2bar = sample mean group 2
S2

= sample

n2

= sample size group 2

deviation group 2

Next, the standard deviation of sample mean group 1 minus the sample
mean group 2 is estimated by the following equation:
S=SQRT (((l(S)-squared) (nl)+ ((52-squared) (n2))
Finally, a static T = (xl bar - x2 bar)/S is calculated, such that the
static T has a t-distribution with degree of freedom given by
df = (SQ (var 1 + var 2))) (SQ(var 1)/(nl-1)
{SQ (var 2)/(n2-l)))

+

where var 1 = SQ (Sl)/nl and var 2 = SQ (S2)/n2
The calculated
11

11

t 11 value is then compared to the established (table)

t 11 value at a 95% confidence interval for the proper degrees of

freedom.

If the calculated

11

t" value is greater than the

11

t 11 value

obtained from a t table, then the two groups being compared are
considered to be significantly different at 0.05 levels of confidence.
In order to determine the effect of splenectomy, pretransplant
transfusion, and ATG administration on graft rejection, data was
calculated and analyzed using the Chi Square (X 2 ) test.
The computer constructs a 2 x 2 table like the one shown
below:
Rejection

Non-Rejection

Splenectomy

fo{fe 1 )

fo(fe 1 )

No Splenectomy

fo(fe 2)

fo(fe 2)
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from the obtained frequencies (fo) an expected frequency (fe) is
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calculated by adding the two obtained frequencies across a now and
then dividing by two:
fe = fo row 1 + fo row 1 /2
column 1
column 2
Chi Square is then calculated by taking the sum of the square of the
differences of obtained and expected frequencies divided by the
expected frequency for each case:
2
( fo-fe)
X2 = E _
_ __
fe
The value obtained is then compared to a table value for the appropriate
degrees of freedom:
df = (r-1) (c-1)
r = row
c = column
If the calculate x2 value is greater than or equal to the table value,
then the two items being compared are considered to be significantly
different at 0.05 confluence level.

CHAPTER III
RESULTS
III.

A Role for Suppressor T Lymphocytes in Renal Transplantation

IIIA-1. Determination of Concanavalin A-Induced T Lymphocyte
Proliferation
Lymphocytes activated by concanavalin A have been shown to
have a suppressive effect on cell-mediated and humoral immune responses
in mice (20-22,166).

Recently, normal human peripheral lymphocytes

activated by concanavalin A have been shown to suppress the proliferative response of similarly isolated lymphocytes to mitogens,
antigens, and allogenic cells (167,168).
Since we were interested in determining the suppressor cell
activity in both healthy adults, as well as in renal transplant
patients, it was necessary to determine the concentration of Con A
which provided the greatest lymphocyte stimulation, i.e. activate
suppressor cell activity.

We first decided to carry out the suppressor

cell experiments using 50 ug Con A/ml ·106 lymphocytes, since similar
activations (167,168) had been carried out with Con A concentrations
of between 40 to 60 ug/ml.

While we obtained decent stimulation, we

were losing a significant number of cells to the 48 hour Con A activation.

Therefore, we decided to carry out the suppressor assay

using three different concentrations (1, 5, and 10 ug/ml·106 cells) of
55

Con A.
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Two examples of our initial attempts to carry out the suppressor

cell assay are shown in Figure 6.

The results indicate that in both

cases, Con A at 5 ug/ml afforded the greatest suppressor cell activity,
i.e. decrease in counts per minute from cells cultured in RPM! 1640
alone (control cells).

However, in a series of subsequent experiments

it was determined that the greatest stimulation, and hence generation
of suppressor lymphocytes occurred when 25 ug/ml of Con A was used
(Table 4).

Since 25 ug/ml Con A gave the greatest stimulation for

both patients and normals (Table 4), the data is normalized so that
Con A at a concentration of 25 ug/ml has a stimulation index of 1.0,
while all the other concentrations of Con A have values of less than 1.0.
Finally, since a large portion of the work was carried out using 5.0
ug/ml Con A, the remainder of the suppressor assays were also carried
out using 5.0 ug/ml Con A to generate suppressor cell activity.
IIIA-2. Suppressor Cell Activity in a Normal Population
As shown in Table 5, the in vitro response of lymphocytes
obtained from the peripheral blood of a healthy, adult volunteer to
mitogen stimulation (PHA and Con A) was suppressed when cultured concomittantly with Con A pre-treated allogenic lymphocytes obtained from
other adult volunteers.
by Shou et

~·

Similar results have been previously obtained

(131) and Hallgren and Yunis (143).

While both groups

were able to demonstrate greater suppressor cell activity, this is
probably due to the fact that they used twice the number of suppressor
cells in the mixed lymphocyte culture assay.
While suppressor cell activity appears to be the rule, there
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Figure 6.

Key:

Two examples of early suppressor experiments using
three different concentrations of Concanavalin A
to generate suppressor cells.

Well A,B Non-stimulated responder cells only.
C,D Suppressor Cells activated with RPMI 1640
only (control) plus responder cells.
E,F Suppressor Cells activated with Con A (1 ug/ml)
plus responder cells ..
G,H Suppressor Cells activated with Con A (5 ug/ml)
plus responder cells.
I,J Suppressor Cells activated with Con A (10 ug/ml)
plus responder cells
No mitogen stimulation
3,4 PHA (100 ug/ml)
5,6 Con A (50 ug/ml)
7,8 Con A (500 ug/ml)

1,2
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Experiment I
~

3,4

1,2

Well

% Supp.

~

5,6

7,8

% Supp.

% Supp.

~

§

A,B

1114

55368

11135

96390

C,D

644

55700

39000

106384

E,F

335

75300

-35

37600

4

73086

31

G,H

1120

61400

-10

10873

72

69846

34

l,J

603

71600

-29

12200

68

85305

20

Well

1,2

3,4

5,6

% Supp.

7,8

% Supp.

A,B

1176

79618

42633

59772

C,D

1584

81791

33528

57829

E,F

2389

64947

21

23601

30

50092

13

G,H

664

56338

31

21344

36

65102

-13

l,J

343

93233

-14

27398

18

96718

-67

Experiment II
~

~

% Supp.

% Suppression = 1 -

~

Columns E,F, G,H, or I,J
Column C,D

X

100

§

Each result represents the average of four wells (runs)

~
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TABLE 4

DETERHINATION OF LYMPHOCYTE BLASTOGENESIS FOR TRANSPLANT
PATIENTS AND NORMAL ADULTS VERSUS THE CONCENTRATION OF
a
CONCANAVALIN A

b

c

Concentration Con A (ug/ml)

Normals

Patients

0

0.01 + 0.01

0.06 + 0.06

1

ND

0.13 + 0.14

5

0.31 + 0.10

0.52 + 0.18

12.5

0.81 + 0.14

ND

d

25

1

d

1
e

33.3

0.46 + 0.14

0.96 + 0

50

0.08 + 0.02

0.81 + 0.47

a

Culture conditions were as follows: zero point one ml of
normal or renal transplant patient's lymphocytes (1 x 106
lymphocytes per ml) in culture media are incubated with
an equal volume of the appropriate mitogen at 37°C for
44 - 48 hours in a 5% C02 environment. Sixteen hours
prior to the termination of the experiment, 0.01 ml of
3H-methyl thymidine is added to each well. The cells are
then harvested, dried overnight, and counted. The results
are expressed as percent stimulation.
b

The normal group consisted of 9 people.
c

The patient group consisted of 8 people.
d

Results are normalized for 25 ug per ml of concanavalin A.
e

This piece of data represents only a single experiment,
where all other results represent at least four experiments.

*Uncertainty

is expressed as + 1.0 S.D.

Table 5
Effect of Con A-Treated Allogenic Lymphocytes on the Mitogenic Response of Normal Human Lymphocytes
Responding
cells
subjects*

eH)Tdr incorporation(cpm) in response to mitogens

Con A
Pretreatment
of allogenic
cell"s§

PHA

lOo]Jg
ml

CON A soHa
ml

% inh

cpm

cpm

CON A

% inh

500

~

ml

cpm

% inh

-17

3302 + 353
4985 + 1338

34

63256 + 4825
71548 + 11912

12

7159
955

85

5107 + 354
14524 + 6801

65

47400 + 22370
84282 + 9483

44

+

91752 +
274
76867 + 14491

-20

3811 + 1391
10357 + 4236

69

64804 + 13597
79077 + 13820

18

4

+

70496 +
95319 +

5137
5334

26

267
705

37

64177 + 10720
76727 + 17041

16

5

+

39781 + 17009
35798 + 13690

-10

3590 + 1446
1438 + 447

-150

444 77 + 11349
44642 + 8849

0

6

+

23994 + 4954
30441 + 11639

21

1502 +
2498 -+

269
780

37

25851 + 11349
28454 + 8849

8

7

+

22691 +
24322 +

4881
4822

8

1175 +
1009 +

256
65

23

29049 +
46962 +

170
1458

38

8

+

16483 +
15391 +

2652
5337

-9

5237 + 938
4927 + 1237

-14

14812 +
17450 +

2349
2417

15

9

+

31081 +
32381 +

2652
8919

5

5047 + 1750
502g1002

3

26899 +
34624 +

1685
2646

23

1

+

55689 + 14203
47317 + 10979

2

+

14678 +
92377 +

3

3472 +
5052 +

+

m
0
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TABLE 5
(continued)

Table 5 Effect of Con A-Treated Allogenic Lymphocytes on the
~·1i togeni c Response of Norma 1 Human Lymphocytes.
* 1.0 ~ 106 normal donor lymphocytes were mixed with 5.0
x 10 t·1itomycin C-treated allogenic control or suppressor
cells in RPMI 1640 plus the appropriat~ mitogen. The
cells were then labeled with 1uCi of ( H-methyl)thymidine and counted.
§Allogenic suppressor cells and allogenic control cells
were incubated in 6RPMI 1640 plus or minus {+ or -)
Con A (5 ug/ml/10 lymphocytes), for 44 - 48 hours. Cells
\·Jere washed, treated with Mitomycin C (50 ug/ml/10 6
lymphocytes), and then washed §gain. The cells were
resuspended, and then 5.0 x 10 lymphocytes were added
to the appropriate well in quadruplicate.
Uncertainty is expressed as + 1.0 S.D.
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were a few instances as seen in our results as well as those of Shou
et al. (131) in which stimulation was noted as opposed to suppression.
In addition, suppressor cell activity was most pronounced when Con A
was the stimulating mitogen.

It should be emphasized that all the

blastogenic activity could be attributed to the responder cell, since
the allogenic, Con A-pretreated suppressor cells had been treated with
mitomycin C, which prevented them from undergoing blastogenesis when
exposed to mitogen stimulation in mixed lymphocyte culture.

Evidence

that this was the case was demonstrated by the fact that Con A pretreated lymphocytes demonstrated only minimal counts of 200 to 2000
cpm which is similar to those of non-pretreated, non-stimulated
lymphocytes; whereas cultures containing responder cells had counts
ranging from 30,000 to 200,000 cpm.
IIIA-3.

Suppressor Cell Activity in Renal Transplantation Patients
Since other groups (99,127) have suggested that suppressor cells

may play a role in renal allograft tolerance, we decided to look at the
suppressor cell activity in renal transplant patients who were at
various stages in their posttransplant history.

Using the mixed

lymphocyte culture assay, as we had previously done for the normal
population, we divided the transplant patients into:four groups based on
their test date, i.e. time from transplant date to when the mixed
lymphocyte culture was carried out.

The results in Table 6 show a

pattern of suppressor cell activity in which the initial activity is
low, then increases, then decreases, and finally is the greatest for
patients who have retained their transplant for at least one year

TABLE 6
Suppressor Effect of Concanavalin A-Treated Lymphocytes from the Peripheral Blood of Renal
Transplant Patients on the Mitogenic Response of Peripheral Blood Lymphocytes from a
Single Healthy Donor(Responder)
Time Posttransplant

Mitogens Used in the Assay
Phytohemagglutinin-P
(100 ug/ml)
(50 ug/ml)
9 + 17

0 - 3 months
(Group I)

N

3 - 6 months

=9

16 + 32

(Group II)

N

=

11

-19b+ 12

6 - 12 months
(Group III)

N

Greater than 12 months
(Group IV)

11

P
p
p

= 0.55
= 0.00*
= 0.10

-18b+ 65

p
p

= 0.00*
= 0.52

4 + 33

p

= 0.00*

=7

24 + 19
N

= 11

~ata is reported as percent suppression
b
11 Negative number represents stimulation

N

N

=9
= 11

-13b+ 12
N

=7

38 + 22
N

=1 -

= 11

a

Concanavalin A
(500 ug/ml)
11

P
p
p

= 0.37
= 0,89
= 0.04*

-18b+ 53

p
p

= 0.63
= 0.01*

3 + 26

p

= 0.17

N

N

=9
= 11

0 + 18
N

11

P
p
p

= 0.30
= 0.37
= 0.10

p
p

= 0.76
= 0.23

p

= 0.11

=7

16 + 19
N

= 11

cpm ConA-treated lymph - cpm NS lymph·.
cpm control lymphocyte - cpm NS lymph.

,C ICC

Statistical significance calculated using student's "t" test and reported in the following manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV; Group II
vs. Group III; Group II vs. Group III: Group III vs. Group IV.

*§Statistically

significant at P < 0.05
Uncertainity expressed as± 1.0 S.D.
0'1

w
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(Group IV, Table 6).

This pattern is observed for both Con A (50 and

500 ug/ml) and PHA (100 ug/ml).

While it was not surprising that

the suppressor cell activity was greatest in patients who had retained
their graft for at least one year (Group IV, Table 6), the decrease
in suppressor cell activity in transplant patients who had their graft
for between 6 to 12 months {Group III, Table 6) was unexpected.
Unlike the results for the normal population, suppressor cell
activity in transplant patients was greatest when PHA was the stimulating
mitoger . In addition, there was greater statistical significance between
the four groups when PHA was the stimulating mitogen.
One fact which is evident is the degree of variability
displayed by the results.

The issue of variability for the mixed

lymphocyte assay has been noted by others· (143, 144), and will be
elaborated on in the Discussion Section.

To lessen the effect of

variability and thus prevent a particular group from being unequally
weighted with respect to time from transplant, experiments were carried
out in a randomized manner.

Thus, on any given day, a patient 6 months

posttransplant was tested along with a patient 2 years posttransplant.
It should be noted that the same patient may appear in more than one
group, because he or she was tested at different times in their posttransplant history.

Moreover, none of the patients that began in the

study dropped out due to graft rejection.
It should be pointed out that experiments were carried out
on transplant patients undergoing acute graft rejection to determine
suppressor cell activity; however, we were unable to complete these

experiments because of excessive lymphocyte loss, either at the
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initial isolation step or after the 44-48 hour incubation with
concanavalin A (suppressor cell activation) (See Discussion).
IIIA-4.

Effect of Splenectomy, Pretransplant Transfusion, and
Antithymocyte Globulin on Suppressor T-cells
Transplant patients for who the mixed lymphocyte culture assay

was carried out, were arranged into four paired groups to determine
the effect of splenectomy, pretransplant transfusion, and antithymocyte
globulin (ATG) on suppressor cell activity.

While individual

differences exist for an individual group and mitogen, there was no
particular pattern nor statistical significance whether or not splenectomy, pretransplant .transfusion, antithymocyte globulin administration
or combinations of these therapeutic measures were utilized.
IIIB.

Acute Rejection and Non-Rejection

JIIB-1.

Comparison of Renal Transplant Patients Experiencing Acute
Rejection and Renal Transplant Patients Not Experiencing
Acute Rejection
In order to determine the differences in renal function,

serology, and effectiveness of three therapeutic measures, i.e.
splenectomy, pretransplant transfusion, and antithymocyte globulin
administration between transplant patients experiencing acute renal
rejection and those showing no signs of acute rejection, a
retrospective study was undertaken.

TABLE 7
Effect of Splenectomy, Transfusion, and Antithyrnocyte(ATG) Administration on
Renal Transplantation of Transplant Patients with Good Renal Function as
Judge by the MLC Suppressor Assay
Therapy

Mitogens Used

Splenectomy
No Splenectomy
(Group I)

PHA 100 ~
ml

CONA 50~
ml

CONA 500 ~
ml

0.18 + 0.30
0.04 + 0.22

-0.16 + 0.65
0,19 + 0.34

0.01 + 0.35
0.02 + 0.15

21, 17

N = 21, 16

-0.01 + 0.23
0.17 + 0.27

0.13 + 0.39
-0.04 + 0.63

0.04 + 0.17
0.04 + 0.32

N = 13, 26

N = 13, 26

N = 13, 25

N =

Antithyrnocyte Globulin
No Antithyrnocyte Globulin
(Group II)

0.02 + 0.24
0.18 + 0.28

Transfusion(Pretransplant)
No Transfusion

~

(Group III)

N

=

16, 23

0.03 + 0.26
0.14
0.27

Splen. and Transfusion
No Splen. and Transfusion

+

N=

(Group IV)
Group
Group
Group
Group

I
II
III
IV

p

= 0.1046

p =
p
p =

=

0.0323*
0.0613
0.2541

-+ 0.54
-+ 0.55

-0.15
0.14
N

= 16,

N

-0.01
0.07

+
- 0.23
-+ 0.31

=

16, 22

23

-0.28 -+ 0.58
0.10 + 0.51

N

-0.06 -+ 0.25
0.07 + 0.28

=

p·=
p =
p =
p =

0.0458*
0.3072
0.1059
0.0757

20, 17

N =

N
p
p

=

= 0.4712
= 0.9899

= 0.3333

p
p =

0.1596

0'1
0'1

TABLE 7

(continued)
a
Data is recorded as percent suppression

=

cpm Con A-treated lymphocytes - cpm NS lymphocytes
1 - ----------------------------------------------------- cpm NS lymphocytes
cpm control lymphocytes
times 100.

b

Negative number represents stimulation.

@
Statistical significance is calculated u·sing the student's "t" test.

*Statistically
fl

significant at P < 0.05.

Uncertainty is expressed as + 1.0 S.D.
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As shown in Table 8, transplant patients experiencing acute
rejection had renal function values indicative of deteriorating renal
physiology; whereas patients showing no signs of acute rejection had
values in the normal range (Table.9).

These findings were expected

since a large part of the diagnosis of acute rejection is based on
the renal function values.
Another finding was that patients experiencing acute rejection
had significantly (P

<

0.05) lower lymphocyte numbers whether they

were obtained from whole blood (clinical), or by Ficoll-Hypaque
density gradient centrifugation (experimental).
patients had significantly lower T cell numbers.

In addition, these
B cell numbers were

also noticeably lower, but not significantly (Table 10).

This was

probably due to the small population of rejection patients.
Finally, acute rejection patients had noticeably (P

< 0~05)

fewer splenectomies, fewer pretransplant transfusions, and were less
often treated with antithymocyte globulin (Table 11).
The mean time posttransplant, i.e. time from transplant to tast
date, was 8.0 months with a range of 0.3 months to 36 months for the rejection group (Group I).

This compares to a mean posttransp1ant time of

17.3 months with a range of 1.0 to 79 months for the non-rejection group.
The male to female ratio was six to one (12 males to 2 females) for the
rejection group (Group I); while the ratio for the non-rejection group
(Group II) was 26 males to 4 females.

Lastly, the blood profiles

(A, B, AB, 0, and not available) were quite different for the two groups

TABLE 8

a
Comparison of Renal Function Tests of Renal Transplant Patients Experiencing
Acute Rejection Versus Renal Transplant Patients With Good Renal Function

Renal Function
Tests
Creatinine

Acute Rejection
(Group I)
3.2 + 1.2
N

BUN

= 16

49.2 + 23.0
N

1Cteat. Clearance

= 15

33.3 + 12.3
N

= 15

b

No Rejection
(Group II)

b

1.5 + 0.4
N

p

= o.oooow

p

= o.oooow

p

= o.oooow

= 113

73.1 +:25.5
N

c

= 112

21.1+7.7
N

Probability

= 102

a

Renal Function Test values obtained from transplant patients at both Foster
bG. McGaw Hospital and Hines VA Hospital.
Acute rejection is defined as whether or not the patient was treated as suggested
by the findings of clinical and diagnotic evaluations.
c
wStatistical significance calcul!ated using student's "t" test.
§Test is significant at P < 0.05
Uncertainty stated as+ 1.0 SD

0'1

'-0

TABLE 9
a
. b
b
b
Normal Values for Total Lymphocyte Numbers , Creatin1ne , BUN , and Creatinine Clearance
Method

Normal Value

Test

Total Lymphocyte Number
d

9
0.06 to 5.5 x 10 /liter
Male:
Female:
Male:
Female:

Creatinine

BUNd

0. 9-1.5
0.8-1.2
0.6-1.2
0.5-1.0

mg/ 100ml
mg/100ml
mg/100ml
mg/100ml

Whole Blood smear and Wright
stain differentialc
Nonspecific Method
Specific Method

7-18 mg/100ml

Creatinine Clearance

d

Male:
105 + 20 ml/min.
Female: 95
20 ml/min.
Male:
117
20 ml/min.
Female: 108
20 ml/min.

+
+
±:

Nonspecific Method
Specific Method

a

Simmons, Arthur, Technical Hematology (3rd edition). 1980. J,B, Lippincott
Company, Phil. Penn. Chpt. III, pp. 93-150,
Faulkner, W.R., and King, J.W., Renal Function Test in Fundamentals of Clinical
Chemistry. Tietz, N.W., ed. W.B. Saunders Company, Phil. Penn, Chpt. 12,
pp. 698-742 (1970).
c
Total Lymphocyte Number = Total White Cell Count/100 x Percent lymphocytes
by differential
~alues found in appendix of Fundamentals of Clinical Chemistry, Tietz, N.W. (ed.)

b

""
0

TABLE 10
Comparison of Serological Tests of Renal Transplant Patients Experiencing
Acute Rejection Versus Renal Transplant Patients with Good Renal Function
Serological Tests

a

Lymphocyte Number
d
Clinical

Acute Rejection
(Group I)

598 + 568
N

Experimental

e

=

14

5.0 + 2.5
N = 16

T-cell Number

f

111 + 94
N

B-cell Number

f

=

13

96 + 192
N = 13

b

No Rejection
(Group II)

b

1263 + 920
N

=
=

= o.oooow

p

= o.oooow

p

= o.oooow

p

=

110

407 + 430
N

p

111

9.6 + 6.7
N

Probabilityc

= 93

191 + 252

0.1285

N = 91

a

Serological Test values obtained from renal transplant patients at Foster G. McGaw and
bRines VA Hospital.
Acute rejection defined as whether or not the patient was treated in accordance with
both clinical and other diagnostic findings.
~Statistical Significance calculated using student's "t" test.
Total lymphocyte number calculated from whole blood by the following formula:
e
Lymphocyte number x Percent Differential = Total Lymphocyte Number
Lymphocytes obtained by Ficoll-hypaque density gradient centrifugation and calculated as
ffor clinically derived total lymphocyte number.
WT- and B-cell numbers obtain by Erythrocy§e Rosetting Technique.
Test is significant at P < 0.05
Uncertainty stated as + 1.0 S.D.

.......
......
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TABLE 11
a,b
.
Comparison of Two Groups
of Renal Transplant Patients
for Three Types of Immune Therapy
I mmune Th erapy

• a
.
Acute Re]ect1on

(Group I)
Splenectomy

Anti-thymocyte
Globulin(ATG)

50%

21%
N

Pretransplant
Transfusion

ect i on b
(Group II)

No~re j

= 14

N

N

= 14

N

29%
N

= 14

n

1.46

= 38

38%
N

3.71

= 38

61%

43%

X2c

0.39

= 38

aPatients experiencing acute rejection of graft at or
baround the time(one month) of testing.
Patients showing no signs of rejection at or near(one
month) the time of testing.
~Statistical Significance calculated using x2 •
Statistically significant using a value of less than 5.0
for one degree of freedom.
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(Table 12).
III.

Age differences are also computed (Table 12).

Effects of Three Different Forms of Therapy on Renal Allograft
Survival.

IIIC-1. Effects of Splenectomy on Kidney Function and the Lymphocyte
Population
Renal transplant patients were divided into four groups on the
basis of whether or not they had their spleen removed, and whether or
not they were experiencing acute rejection.

As can be seen in Table 13,

patients not experiencing acute rejection had renal function values
which were very comparable, whether or not they had their spleen removed.
In addition, the renal function values for the non-rejection group was
significantly different from the rejection group.

Since none of the

patients currently experiencing acute rejection had a splenectomy,
there are no values for Group III (Splenectomized, rejection patients).
It should be pointed out that four of the patients who had a
splenectomy suffered a rejection episode early in their transplant
history.

However, three of these patients had excellent functioning

grafts at the time of testing, while the fourth suffers from chronic
rejection.

Therefore, these four patients were counted as splenect-

omized, non-acute rejection patients (Group I, Tables 13 and 14). Thus,
in Table 11, where we are interested in determining the effect of splenectomy, pre-transplant transfusion, and ATG administration on preventing
acute rejection; thus, the patients were divided into two groups on the
basis of whether they have ever-experienced an acute rejection episode,
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TABLE 12

Comparison of the Mean Time Posttransplant, Male to Jemale Ratio,
and Blood Types for Acute Rejection. and Non-Rejection Transplant
Patients

Characteristics

Acute Rejection

Non-Rejection

(Group I)

Mean Time Posttransplanta

8.0 + 13.7 months
N = 37b
0.3 to 36 months

Range
Male/Female

12/2
45.2 + 10.7yearsC

Age
Blood Profile
Type A
B
AB
0

7
3
0
3

N.A.d

1

(Group II)

17.3 + 17.0 months
N = 131b
1.0 to 79 months
26/4
38.7 + 11.5 yearsc
10
5
1
9
9

a
Represents the mean time from transplant to test date.
b
Represents the number of tests
c
Represents the patient's age as of
d
Value not available

*Uncertainty

expressed as+ 1.0 S.D.

.Significant at P 0.05

TABLE 13
a

b

Comparisons Between Splenectomized

and Non-Splenectomized Renal Transplant Patients
c
For Three Renal Function Tests.
d

Renal Function
Tests

Creatinine

BUN

Splenectomized
Non-Rejection
Patients
(Group I)

Non-Splenectomized
Non-Rejection
Patients
(Group II)

1.5 + 0.4

N= 90

N = 61

N = 90
Creat. Clearance 70.1 + 23.4
N = 83

Non-Splenectomized
Rejection
Patients
(Group IV)

Probability

e

1.4 + 0.4

21.4 + 7.0

Splenectomized
Rejection
Patients
(Group III)

22.1 + 8.2

3.2 + 1.2

N.A.

N = 17
N.A.

e

N = 61
71.6 + 25.4
N = 59

48.9 + 22.3
N = 16

N.A.

e

34.1 + 12.3
N = 16

p = 0.2218
p = 0.0000*
p = 0.0000*
p = 0.6085
p = 0.0000*
p = 0.0000*
p = 0.7025
p = 0.0000*
p = 0.0000*

a

Spleen removed prior to the transplant.
b

Splenectomized and non-splenectomized patients maintained on different, individualistic
immunosuppressive regimes. In addition,patients may have also received transfusions and/o.r
ATG treatment.
c

Renal Function Test values obtained from transplant patients at both Foster G. McGaw Hospital
and Hines V.A. Hospital.
-....!
(.)'1

TABLE 13

(continued)
d

Statistical significance calculated using student's "t" test and reported in the following manner:
Group I vs Group II, Group I vs Group IV, and Group II vs Group IV for each test.
e

None of the patients currently (within one month of the test) experiencing rejection had a
splenectomy.

*Test

is significant at P

~

0.05

Uncertainty is expressed as± 1.0 S.D.
N represents the number of tests

"-J

m

TABLE 14
a
b
Comparisons Between Splenectomized and Non-Splenectomized Renal Transplant Patients
For Lymphocyte Numbers, T-Cell Numbers, and B-Cell Numbers
c

d

Serological Test

Splenectomized
Non-Rejection
Patients
(Group I)

Non-Splenectomized
Non-Rejection
Patients
(Group II)

Splenectomized
Rejection
Patients
(Group III)

e
Lymphocyte Number

g

1569 + 977
N

= 88

1135 + 680
N

= 57

N

=

15

p
p
p

= 0.0020*
= 0.0000*
= 0.0029*

p
p
p

= 0. 7741
= 0.0000*
= 0.0000*

p
p
p

= 0.0369*
= 0.0604
= 0.6074

g

496 + 477
N

= 71

472 + 420
N

110 + 94

N.A.

= 46

N

f
B-Cell Number

580 -+ 552

N.A.

f
T-Cell Number

Non-Splenectomized Probability
Rejection
Patients
(Group IV)

=

13

g

218 + 259
N

=

72

128 + 201
N

N.A.

= 45

96 + 192
N

=

13

a

Patients had their spleen removed prior to their transplant.
b

Splenectomized and non-splenectomized patients maintained on different, individualistic
immunosuppressive regimes. In addition, patients may have also received transfusions and/or
ATG treatment.
c

Serological Test values obtained from renal transplant patients at both Foster G.McGaw Hospital
and Hines V.A. Hospital.
d

Statistical significance calculated using student's "t" test and recorded in the following manner:

:::1

TABLE 14
(continued)
Group I vs Group II, Group
e

Total Lymphocyte Number

I~

= Total

Group IV, and Group II vs Group IV for each serological value.

White Blood Cell Count/100 x Percent Lymphocytes from Differential.

f

T-cell and B-cell numbers calculated using an erythrocyte-resetting technique in the following
manner:
T-Cell Number = Total Lymphocyte Number x Percent T-Cells
g

None of the patients currently (within one month of the test date) experiencing a rejection
episode had a splenectomy.

*

Test is significant at P< 0.05.

Uncertainty is expressed as+ 1.0 S.D.
N refers to the number of tests

-....,J
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and then analyzed for the individual therapeutic modality.
hand,

On the other

in Tables 13, 14, 16, 17, 19, and 20 we are interested in the con-

tribution that the particular therapeutic measure had on the renal
physiology of the transplant patient at or near (within one-year) the
time of testing.

Therefore, these tables contain several patients

who have suffered a rejection episode early in their transplant history,
but within one-year of testing had excellent functioning grafts, and no
further rejection episodes.
Non-splenectomized, non-rejection transplant Jtients exhibited
significantly (P

<

0.05) fewer total lymphocyte numbers and 8-cell

numbers than the splenectomized, non-rejection transplant patients
(Table 14). The T-cell numbers were practically the same for the two
groups.

Total lymphocyte numbers, T- and 8-cell numbers for the non-

splenectomized, rejection patients were significantly (P

<

0.05) less

than either of the two groups (Groups I and II).
Statistical analysis, i.e. student's "t" test, showed that both
splenectomized and non-splenectomized groups (Groups I and II) of nonrejection transplant patients were comparable (P

>

0.4) with regards

to the mean time posttransplant (Table 15). The mean time posttransplant for the non-splenectomized, rejection group (Group IV) was
nificantly (P

<

sig~

0.05) less than either of the non-rejection groups

(Groups I and II, Table 15).
IIIC-2.

Effect of Pretransplant Transfusion on Renal Allograft
Function and on Lymphocyte Number
For the purpose of analySis, renal transplant patients were

TABLE 15
Comparison of Mean Time Posttransplant, Male to Female Ratios, and Blood Types for
Splenectomized Non-Rejection, Non-Splenectomized Non-Rejection, and Non-Splenectomized
Rejection Transplant Patientsa
Characteristics

Splenectomized
Non-Rejection
Patients
(Group I)

Mean Time PostTransplant

17.5 + 16.9 months

Range

1 - 60.0 months

Male/Female

N = 90

19/4

Blood Profile
Type
A

8

B
AB

1
0

0

8

NAc

6

Non-Splenectomized
Non-Rejection
Patients
(Group II)
15.7 + 17.0 months

N

= 63

0.3- 79 months
19/4
7
6
1
4
5

Non-Splenectomizedb
Rejection Patients
(Group III)
1.8 + 0.6 months

N = 17
0.2 - 5 months
5/1
3
1
0
1
1

a

Splenectomized and non-splenectomized renal transplant patients at both
bFoster G. McGaw Hospital and Hines V.A, Hospital.
None of the patients experiencing rejection had a splenectomy.
c
§Values not available.
Uncertainty expressed as± 1.0 S.D.
N refers to the number of tests
co
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TABLE 16

Comparison of Renal Transplant PatientsaReceiving Pretransplant Transfusions
Those Not Receiving Pretransplant Transfusions
Transfused
Non-Transfused
Renal Function
Transfused NonNon Transfused
Rejection
Rejection
Rejection Patient
Non-Rejection
Test
Patient
Patient
Pabient
(Group
II)
(Group
III)
(Group
IV)
(Group I)
1.3 + 0.4

Creatinine

N

= 77

21.1 + 7.7

BUN

N

Creat. Clearance

=

78

76.1 + 26.3
N

= 73

1.6 +
- 0.4
N

=

72

21.2 + 8.4
N

=

72

67.1 + 17.8
N

= 67

3.6 + 0.7
N

=

5

66.0 + 26.0
N

=5

33.5 + 8.6
N

=4

3.0 + 1.3
N

=

12

41.1 + 16.2
N

=

11.

34.2 + 13.6
N

=

12

b

and
Probabilityc

p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p

= 0.0000*
= 0.0018*
= 0.0000*
= 0.0030*
= 0.0028*.
= 0.2789
= 0.9945
= 0.0185*
= 0.0024*
= 0.0186*
= 0.0025*
= 0.1056
= 0.0188*
= 0.0002*
= 0.0000*
= 0.0022*
= 0.0000*
= 0.9027

~enal Function Test values obtained from renal transplant patients at both Foster G.
bMcGaw Hospital and Hines V.A. Hospital.
Transfusions consisted of whole blood, red blood cells, packed red blood cells, washed
cells, plasma, and combinations of the five.
cStatistical significance calculated using student's "t" test and reported in the following
manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV; Group II vs.
*
Group III; Group II vs. Grou~ IV; and Group III vs. Group IV.
Test is significant at P < 0.05.
Uncertainty expressed as + 1.0 S.D.
(X)

......

TABLE 17
a
b
Comparison of Renal Transplant Patients Receiving Pretransplant Transfusions
and Those Not Receiving Pretransplant Transfusions
Serological Test

Transfused NonRejection Patients
(Group I)

Total LymHhocyte
Number

T-Cell Number

e

1242 + 957
N

e

75

439 + 449
N

B-Cell Number

=

= 64

186 + 253
N

= 65

Non-Transfused
Non-Rejection
Patients
(Group II)

Transfused
Rejection
Patients
(Group III)

Non-Transfused
Rejection
Patients
(Group IV)

1464 + 837

528 + 462

599 + 601

N

=

70

550 + 455
N

=

53

181 + 227
N

= 52

N

=4

122 + 119
N

=4

61 + 51
N

=4

N

=

10

99 + 86
N

=

10

36 + 38
N

=

9

Probabilityc

p
p
p
p
p
p
p
.p
p
p
p
p
p
p
p
p
p
p

= 0.1374
= 0.0496*
= 0.0073*
= 0.0205*
= 0.0007*
= 0.8162
= 0.1896
= 0.0030*
= 0.0205*
= 0.0007*
= 0.0000*
= 0.7467
= 0.9108
= 0.0065*
= 0.0000*
= 0.0091*

= 0.0001*.
= 0.4453

aSerological values obtained from transplant patients at both Foster G. McGaw Hospital
band Hines V.A. Hospital.
Transfusions concisted of whole blood, red blood cells, packed red blood cells, washed
blood cells, plasma, and combinations of the five.
cStatistical significance calculated using student's "t" test and reported in ·the
following manner: Group I vs. Group II; Group I vs •. Group III; Group I vs. IV; Group II
vs. Group III; Group II vs. Group III; and Group III vs. Group IV.
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TABLE 17

(continued)
d

Total lymphocyte number calculated from whole blood in the following manner:
Total lymphocyte number

= Total

White Blood Cell Count/100 x Percent of lymphocytes
by differential
e
*T-cell and B-Cell numbers calculated by e~ythrocyte-rosetting technique.
Statistically significant at P < 0.05.
Uncertainty expressed as ± 1.0 S.D.
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divided into four groups on the basis of whether or not they had received
a pretransplant blood transfusion, and whether or not they had currently
(within one-year) suffered a rejection episode.

Transfusions consisted

of either whole blood, red blood cells, packed red blood cells (148),
washed cells, or combinations of the four.
As was the case with splenectomized patients (Section IIIC-1),
there are several patients who had a rejection episode early in their
transplant history, but at the time of testing had normal functioning
grafts.

Therefore, these patients were counted as non-rejection patients.
The results in Table 16 show non-rejection, pretransplant trans-

fused patients exhibited significantly (P

<

0.05) lower creatinine values

than the non-rejection, non-transfused transplant patients.

In addition,

creatinine clearance values were also significantly different for the
same two groups.

Blood Urea Nitrogen (BUN) values on the other hand,

were not statistically different (P = 0.1945) for the two groups (Groups
I and II).

Significance differences (P < 0.05) are seen between Groups

1 and II, I and IV, II and III, and II and IV, Table 16. While creatinine and creatinine clearance values are similar--for the two rejection
groups, BUN values are noticeably lower in the non-transfused group
(Group IV).
Total lymphocyte, T-cell, and B-cell numbers are statistically
similar for non-rejection patients, whether or not they were transfused (Groups I and II, Table 16) prior to transplant.
ical differences of (P

<

Again statist-

0.05) are seen between non-rejecting groups

(Groups I and II) and rejection groups (Groups III and IV), whether or
not either group received a pretransplant transfusion.

Lymphocyte

85

numbers, T-cell, and B-cell numbers appear to be equivalent for both
rejection groups (Groups III and IV}.
The mean time from transplant to test date for both transfused
and non-transfused (pretransplant) patients are almost identical
(P = 0.94).{Groups I and II, Table 18). Statistical differences of
P = 0.00 in the mean time posttransplant are noted between the nonrejecting groups (I and II) and rejecting groups (III and IV) (Table 18).
Finally, the

t~o

plant times (P

>

rejection groups (III and IV) have similar posttrans0.5).

The representative blood types, and male to

female ratios are also shown in Table 18.
IIIC-3.

Effects of Anti-Thymocyte Globulin (ATG) Administration on
Renal Allograft Function and on Total Lymphocyte, T-Cell, and
B-Cell Numbers
Non-rejection transplant patients have similar creatinine, BUN,

and creatinine clearance values whether they received ATG or not (Table
19). Again, as was the case for splenectomized and pretransplant,
transfusion patients, patients currently experiencing a rejection
episode (Groups III and IV) have significantly (P

<

0.05) poorer renal

function values than the non-rejection patients.(Groups I and II).

Renal

function values for the two rejection groups (III and IV) are measureably
different.

Patients who experienced a rejection episode within one month

of the test date and had received ATG have decidedly lower creatinine
and BUN values, and statistically higher creatinine clearance values than
rejection patients who did not receive ATG.
As was the case for both-_splenectomy and transfusion data,

TABLE 18

Comparison of Mean Time Posttransplant, Male to Female Ratio, and Blood Types
for Pretransfused Non-Rejection. Non-Transfused Non-Rejection, Transfusion
Rejection, and Non-Transfused Rejection Transplant Patients
Characteristics

Transfused NonRejection Patients
(Group I)

Mean Time Posta
transplant

16. 1 + 15. 2 months
.

Range

1 - 58.0 months

Blood Profile
Type A
B

N.A.

= 82

22/4

Male/Female

AB
0

N

b

Non Transfused
Non-Rejection
Patients
(Group II)
17. 8 -+ 18. 6 months
N

1 - 79 months
14/6

9
3

5

1

0
2
9

11
3

= 74

4

Transfused
Rejection
Patients
(Group III)

Non-Transfused
Rejection
Patients
(Group IV)

2. 3 + 1. 3 months 1. 7 + 1. 4 months
N= 4
1 - 4 months

2/0
0
1
0
0
1

N = 12
0.2 - 5 months
3/1
3
0
0
0

1

~Represents the mean time from transplant to testing.
§Values not available.
Uncertainty expressed as + 1.0 S.D.
N refers to the number of-tests.
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TABLE 19
Comparison of Renal Transplant Patients Receiving Antithtymocyte Globulin(ATG) and Those
Not Receiving ATGa
Renal Fugction
Test

ATG-Nonrejection
Patients
(Group I)

Creatinine

BUN

1.5 + 0.4

No ATG
Non-Rejection
Patients
(Group II)
1.5 + 0.6

N = 52

N = 101

22.8 + 7.8

22.0 + 10.1

N

= 51

N

= 99

ATG-Rejection
Patients
(Group III)
2.6 + 0.2

No ATG
Rejection
Patients
(Group IV)
3.4 + 1.3

=4

N = 12

43.0 + 0.8

51.5 + 26.9

N

N

=4

N = 9

Probabilityc

p
p
p
p
p
p

p =
p
p =

p

71.9 + 28.2
N =

45

70.8 + 21.3
N

= 98

48.0 + 3.9
N =

4

27.9 + 9.5
N = 11

0.6254

= 0.0000*

p
p

Creat. Clearance

= 0.6391
= 0.0000*
= 0.0000*
= 0.0000*
= 0.0001*
= 0.0608

p
p
p

0.0056

= 0.0000*
= 0.0048*
= 0.3219
= 0.8075
= 0.0000*
= 0.0000*

p

= 0.0000*

p
p

= 0.0000*

= 0.0000*

:Horse Anti-Human Thymocyte Globulin
Renal Function Test values obtained from renal transplant patients at both Foster G.
McGaw Hospital and Hines V.A. Hospital.
cStatistical significance calculated using student's "t" test and reported in the
following manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV;
*
Group II vs. Grou~ III; Group II vs. Group IV; Group III vs. Group IV.
Test is significant at P < 0.05
Uncertainty expressed as ± 1.0 S.D.
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patients who have not experienced a rejection episode within one-year
of the test date, are considered as non-rejection transplant patients.
Both non-rejection groups (I and II) have similar lymphocyte,
T-cell, and 8-cell numbers (Tab1e 20).

The values for the two rejection

groups (III and IV) are decidedly less than those for the non-rejection
groups (I and II) (Table 20), with only the lymphocyte number for the
rejection which received ATG not being significantly different from
the two non-rejection groups.

Finally, rejection patients who

received ATG demonstrated greater lymphocyte and T cell numbers than
the rejection group (Group IV) which did not receive ATG (Table 20).
8 cell numbers for the two rejection groups (III and IV, Table 20)
are statistically comparable (P

= 0.68).

The mean time posttransplant for the two non-rejection groups
(l and II} are approximately the same (Table 21).

The mean time post-

transplant for rejection patients whom were treated with ATG (Group IV,
Table 21} is significantly shorter than either non-rejection group
(Group I and II). Since there was only a single individual who
received ATG and experienced a rejection episode within one-year of
testing, this category (Group III --- ATG, Rejection Transplant
Patients) is not subject to statistical analysis.

Finally, male to

female ratios, and the blood types of all ATG-treated, and non-ATGtreated transplant patients are also presented in Table 21.

TABlE 20
a
Comparison of Renal Transplant Patients Receiving ATG and Those Not Receiving ATG
b
Probabilityc
No ATG
Serological Test
ATG
ATG-Non
No ATG NonRejection
Rejection
Rejection
Rejection
Patients
Patients
Patients
Patients
(Group I)
(Group II)
(Group III) (Grpup IV)
Total Lymphocyte
Number

T- Cell Number

e

d

1411 + 958
N = 48

504 + 465
N

B-Cell Number

=

40

164 + 260
N

= 39

1358 + 892
N

= 95

457 + 462
N

=

79

182 + 216
N

= 77

909 + 577
N

=3

198 + 89
N= 2

30 + 38
N

=2

514 + 562
N

=

11

94 + 90
N

=

11

47 + 46
N

=

10

p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p

= 0.7357
= 0.2970
= 0.0004*
= 0.3241
= 0.0005*
= 0.3682
= 0.6101
= 0.0252*
= 0.0000*
= 0.0865
= 0.0000*
= 0.3718
= 0.7043
= 0.0240*
= 0.0106*
= 0.0249*
= 0.0000*
= 0.6793

~orse anti-human thymocyte globulin.
Serological Test values obtained from transplant patients at both Foster G. McGaw
Hospital and Hines V.A. Hospital.
cStatistical significance calculated using student's "t" test and reported in the
following manner: Group I vs. Group II; Group I vs. Group III; Group I vs. Group IV;
Group II vs. Group III; Group II vs. Group IV; and Group III vs Group

OJ
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TABLE 20
(continued)

dTotal Lymphocyte Number = Total White Cell Count/100 x Percent Lymphocyte by differential.
e
*T-cell and B-cell number calculated using erythrocyte-rosetting technique.
§Test is significance at P < 0.05
Uncertainity expressed as ± 1.0 S.D.
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TABLE 21

Comparison of Mean Time Posttransplant, Male to Female Ratios, and Blood Types
for ATG-Non-Rejection , No ATG-Non-Rejection, ATG-Reje~tion, and No ATGRejection Transplant Patients
ATG
Non-Rejection
Patients
(Group I)

Characteristics

+ 15.1 mo.

Mean Time P~st
transplant

15.1

Range

1.5 - 56 mo.

N = 53

Male/Female

17/1

Blood Profile
Type A
B

AB
0

N.A.

c

6
3
0
6
3

No ATG
Non-Rejection
Patients
(Group II)
17.~

ATG
Rejection
Patients
(Group III)

No ATG
Rejection
Patients
(Group IV)

+ 18.1 mo. 2.5 + 1.3 mo. 1.5 + 1.3 mo.
-

N = 97
0.25 - 79 mo.
21/8
8

4
1
7
9

N= 5
0.5 - 4 mo.

N = 12
0.25 - 5 mo.

0

4/1.

0
0
0
1
0

3
1
0
0
1

a

ATG administered and non-ATG administered transplant patients obtained from both
bFoster G. McGaw Hospital and Hines V.A. Hospital.
Time from transplant to testing.
c
§Values not available
Uncertainty expressed as ± 1.0 S.D.
N refers to the number of tests
0.0
1--'

CHAPTER IV
DISCUSSION
IVA.

Suppressor T-Lymphocytes

IVA-1.

Suppressive Effects of Concanavalin A-Treated
Allogenic Lymphocytes on Normal Human Lymphocytes
in a One-Way Mixed Lymphocyte Culture (MLC)
Every person goes through life surrounded by potentially harm-

ful microorganisms.

Those that invade the body are usually kept in

check by the body's immune defenses, an elaborate system that stands
geared to intercept and destroy foreign cells (170).

At the same

time, an individual's immune system must not react too vigorously to
invasion by these microorganisms.

Finally, an individual's immune

system must be capable of recognizing self from nonself, so as not to
destroy the body's own cells.

Therefore, it has become increasingly

evident that the immune system possesses a mechanism(s) of checks and
balances, so it can prevent the excessive reaction to a multitude of
stimulations throughout the lifetime of that individual.
The role of antigen-specific and mitogen-activated (nonspecific) suppressor lymphocytes in the regulation of humoral and cellmediated immune responses has been previously demonstrated (16, 20, 5763).

In addition, lymphocytes isolated from spleen and activated by

Concanavalin A have been shown to inhibit the antibody response of
plaque-forming cells (PFC), mixed lymphocyte culture reaction (MLC)
92
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and the generation of cytotoxic cells in cell-mediated lympholysis
(CML) (20-22).
Like suppressor cells isolated from the central immune tissue
of mouse, peripherally blood-derived lymphocytes also appear to exhibit
suppressive actions.

Evidence has been accumulated implicating sup-

pressor cells isolated from peripheral blood as being involved in the
etiology and pathogenesis of a number of pathologic states (66-68,
171-173).

Thus, if suppressor cells represent a mechanism for modula-

ting immune responses, and are found in the peripheral blood of
individuals experiencing several disorders, then one might also expect
to find suppressor cells in the peripheral blood of normal, healthy
individuals.
Indeed, our data shows (Table 5) that Con A-pretreated lymphocytes isolated from the peripheral blood of healthy, adult volunteers,
suppress the proliferative response of similarly isolated allogenic
lymphocytes.

These findings confirm the earlier work of Shou et al.

(167) and Hallgreen and Yunis (169).
Since blastogenesis with non-specific mitogens, such as phytohemagglutinin (PHA) and Concanavalin A (Con A) can involve either B
or T lymphocytes, our results do not distinguish whether the suppressive effects were due entirely to the inhibition ofT-cell proliferation.

However, work by Shou et al. (167) with pokeweed mitogen

(PWM), a potent B-cell stimulator, shows less suppressive activity
(Figure 7) than the T-cell mitogens Con A and PHA; and this suggests
that the suppressor cells act mainly at the level of the T-cell.
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Ffgure 7.

Effect of Con A-Treated Allogenic Lymphocytes on
the Mitogenic Response of Normal Human Lymphocytes
from Table 1 of Suppressor Cell Activity after Concanavalin A Treatment of Lymphocytes from Normal Donors,
Shou et ~- (167}.

L{)

en

Responding
Cells (subjects)*

( 3H) TdR II1_ce>_rporation (cpm) in Response toMi togens4=

Con A
Pretreatment
of allog~nic
Cells~

cpm

1

-

18.6

74,450 + 3,270
. 37,576 + 653

49.5

65.035 + 3,227
34,945 + 1,753

46.3

13' 136 + 354
13,979 + 1,026

-6.4

126,324 + 5,395
9> ~479 + 3,772

28.4

85,958 + 2,878
57,860 + 519

32.4

44,285 + 1,700
27,285 + 372

38.4

73,138 + 3,056
59,999 + 2.375

18.0

94,328 + 3,366
52,759 + 1,717

44.1

15,583 + 1,319
15,312 + 467

1.7

38,650 + 2,850
28,215 + 1,417

27.0

128,362 + 6,229
96,491 + 1,266

24.8

11,445 + 688 -61.6
18,493 + 1,384

-

93,639 + 2,850
58,501 + 2,903

37.3

188,524 + 4,585
117,377 + 5,896

37.7

21,278 ± 629
20,857 + 1,521

2.0

-

43,991 + 3,244
26,553 + 392

39.7

125,332 + 4,969
69,036 + 888

44.9

19,778 + 2,068
10,539 + 713

46.7

-

60 '334 + 6 '856
38,119 + 554

36.8

146,836 + 6,190
73,787 + 3,172

49.7

12,390 +
16,001 +

-

+
7

+
8

% inh.

37,349 + 369
30 '40 1 + 2 '89 7

+
6

cpm

27.2

+
5

% inh.

121,521 + 4,213
88,444 + 6,356

+
4

cpm

13.8

+
3

% inh.

87,828 + 6,684
75,742 + 5,566

+
2

PVM
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+

515 -29.1
835
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*5.0

x 104 normal donor lymphocytes were mixed with an equal
number of MC-treated allogenic control or suppressor cells in
RPMI plus designated mitogen and labeled with 2 uCi (3H)thymidine
((~)TdR) as described inKaterials and Methods. Each pair of
cultures consists of responder lymphocytes from a different
subject donor.
:j:
Allogenic lymphocytes were incubated in RPMI plus or minus Con A
(60·.ug/ml) for 48 hr. Cells were washed, treated with MC
(50 ug/ml) for 30 min, washed again, and resuspended in RFMI.
5.0 x 104 allogenic cells were added to each culture well.

0

Counts per minute of (3H)TdR incorporated represents the mean of
3 -4 replicate cultures + the standard deviation
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Additional evidence that normal, healthy adults possess suppressor cells capable of inhibiting cell-mediated immune responses,
comes from experiments utilizing the same lymphocyte, i.e., autologous lymphocytes, as the responder and suppressor cells.

Shou et al.

(167) and Jayavant et al. (73), have shown that lymphocytes pretreated
with Con A suppressed the proliferative response of autologous lymphocytes.

We have also attempted several suppressor experiments using

autologous lymphocytes, but have only a single experiment to show for
these efforts.

The one experiment did show (data not shown) that

incubation of lymphocytes with autologous Con A-pretreated lymphocytes
resulted in a 20% suppression of the lymphocyte proliferative response.
These observations are consistent with a model which proposes that
individual stimuli are prevented from initiating an uncontrolled
immunologic chain reaction through the intervention of suppressor cells
capable of abrogating the response (167).
Another factor to be considered is whether the inhibition of
proliferative responses is entirely due to suppressor cells, or possibly due to cytotoxic cells acting directly on the responder lymphocyte, and thus preventing its proliferation, i.e., blast formation
as measured by the uptake of 3H-thymidine. Several lymphocyte stimulators, such as PHA and allogenic and xenogenic (originating from a
different species) antigens have been shown to elicit immunospecific
cytotoxicity (174).

However, studies by Perlmann et al. (175) have

shown that Con A not only fails to generate such cytotoxicity, but it
can even inhibit PHA-induced cytotoxic effects.

Thus, it appears that

most humans possess a population of suppressor lymphocytes which, when
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activated by Con A, can suppress both cell-mediated and humoral immune
responses.
Finally, as seen in our studies, and as noted by other groups
(167,

173)~

a few examples of stimulatory activity have been observed

in the mixed lymphocyte reaction assay.

The failure to manifest sup-

pressor activity may be attributed to the presence of stimulatory
non-T lymphocytes and other non-lymphocylic cells in the mixed lymphocyte reaction mixture.

Semenzato et al. (176) has demonstrated the

existence of non-T-cells, lacking the C3 (Complement 3) receptor, which
are capable of stimulatory lymphocytes, and thus decreasing or even
abrogating the effects of suppressor T-cells.

Another possible ex-

planation for the lack of suppressor activity might involve a Con A
receptor.

Shou et al. has suggested that ·can A can act through more

than a single receptor; one site responsible for triggering blast
transformation, and another for initiating suppressor activity.

Thus,

cells which fail to be induced to manifest suppressor functions, but
can undergo blast transformation, may lack a second receptor.

Subse-

quent studies have shown suppressor lymphocytes to be a non-proliferative cell, i.e., does not require blast transformation for its activity
{177, 178).

Therefore, a more plausible explanation might be that the

individual failing to manifest suppressor activity, might lack or
possess ineffective suppressor T lymphocytes; and the resulting stimulation might be due to Con A-stimulation of lymphoproliferative species
able to realize their full potential in the absence of suppressor
activity.

Finally, the lack of suppression in those few examples might

merely reflect the physiological state of the individual on that given
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day.

Individuals exposed to a stressful situation,

s~ch

as running

(179), have been shown to possess lymphocytes which exhibit reduced
responsiveness to the mitogens PHA and Con A.

In addition, it is also

possible that stress which elevates plasma cortisol levels, decreases
both T and B-cell levels in circulation (179, 180); and this in turn
contributes to the diminished suppressor activity of peripherallyobtained blood lymphocytes.
IVA-2.

Suppressive Effects of Concanavalin A-Treated
Allogenic Lymphocytes on Lymphocytes Obtained
from Renal Transplant Patients with Good Renal Function
Suppressor cell activity exhibited by renal transplant patients

experiencing good renal function, follows ·the pattern exhibited by the
Normal group (Table 5), but the overall suppressor cell activity displayed by the transplant group was decidedly less than that of the
Normal group.

While the two groups differ with respect to physical

characteristics such as age and probably renal function, i.e., creatinine, creatinine clearance, and BUN, the major reason for the decrease
in suppressor cell activity is that the transplant patients are receiving
exogenous steroids.

Several groups have previously shown that

corticosteroids administered both in vitro (181) and in vivo (181-186),
suppress the response of lymphocytes to stimulation by mitogens and
antigens, and enhanced the generation of antibody-secreting cells possibly by inhibiting suppressor cells (187-189).

Clarke et al. (186)

showed that prednisolone suppressed the mitotic response of lymphocytes
to sub-maximal stimulating doses of PHA, four hours after prednisolone
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administration, returning to normal by twenty-four hours.

Finally,

Duclos et al. (190) showed that transplant patients receiving daily
doses of azathioprine (2-3 mg/kg) and prednisolone (0.25 mg/kg), had
significantly less suppressor activity (37 percent ~ 14 percent) than
+

.

normal volunteers (89 percent- 6 percent), as JUdged by the Jerne
plaque assay, i.e., a measure of antibody-forming cells/10 6 collected
cells.

As for the mechanism of steroid action, the evidence suggests

that steroids act directly on the suppressor T-cells (189,190).
An unexpected finding of our study with renal transplant
patients is the pattern of suppressor cell activity exhibited by the
different posttransplant groups (Table 6).

If, in fact, suppressor

T-cells do play a major role in graft survival, then one would expect
to see increasing suppressor cell activity with the increasing period
of graft retention.

However, instead of increasing, the suppressor

cell activity for the six-to-twelve-month group of patients (Group III,
Table 6) decreased.

While the decrease is only statistically signifi-

cant (p <0.01) when PHA is the stimulating mitogen, the pattern is the
same for both concentrations of Con A.

In an effort to explain these

findings, one has to consider the effect of experimental (design), change
in drug therapy, or physiological factors as being responsible for the
decrease in suppressor cell activity.

If all the patients in the

six-to-twelve-month group were tested at the same time, this might
explain the decrease in suppressor cell activity.

However, the experi-

ments were carried out in a random manner, i.e., a patient in one time
group was tested along with patients from one of the other time groups;
thus, it is unlikely that this type of experimental error is responsible
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for the observed pattern of suppressor cell activity.

The second ex-

planation, changes in drug therapy, also does not totally explain the
observed pattern of suppressor activity, since steroid administration
remained constant or decreased after the initial three months posttransplant.

It should be noted that changes in the dosage of Imuran

(azathioprine) occurred throughout the different posttransplant periods
for some of the patients; and these changes may have contributed to
the observed decreased suppressor cell activity seen in the six-totwelve-month group.

Therefore, it appears that the decrease in sup-

pressor cell activity might reflect a change in the immune status of
those patients; however, the nature of these changes is unknown at this
time.
IVA-3.

Suppressor T Cell Activity in Renal Transplant
Patients Undergoing Acute Rejection of the
Kidney Graft
One of the goals of this thesis was to determine the role of

suppressor T-cells in acute rejection, and determine whether the assay
used to measure suppressor activity could be used to predict impending
acute rejection.

However, we were unable to obtain results of this type

due to the requirement for large numbers of lymphocytes needed to
carry out the experiments, i.e., 12 x 106 lymphocytes per patient.
In addition, we were involved in another study of recently-transplanted
patients, and thus their availability to our study was limited.
In a recent study of allograft rejection, Jayavant et al.
(73) demonstrated that suppressor activity paralleled renal function.

102
In a prospective study of living-related recipients, .they found that
patients who were experiencing acute rejection and/or had subsequent
(1-3 months posttransplant) loss of their graft, suppressed the proliferation of autologous lymphocytes by 33 to 77 percent; whereas,
transplant patients with good renal function (creatinine of less than
1.5 mg/dl) had suppressor cell activity measured at 88 to 98 percent.
A retrospective study of cadaver recipients showed a suppression of
greater than 85 percent to be typically associated with excellent longterm allograft function.

In contrast, patients with suppressor cell

activity of less than 80 percent, were shown to have experienced graft
rejection.

When the successes (excellent allograft function) from

both living-related recipients and cadaver recipients were combined,
they were shown to have a composite suppressor cell activity of 89.5
percent, as compared to a suppressor cell activity of 51 percent for
the failures (graft rejection or loss) for both groups, P

<

0.05

When the two groups were compared for their ability to suppress allogenic lymphocyte proliferation, a similar pattern of suppressor cell
activity was observed, but the two groups (successes vs. failures)
were not significantly different.

In addition, the results were simi-

lar, only the magnitude being different, whether the suppressor cell
was treated or not with Con A.

While this study demonstrates a rela-

tionship between magnitude of suppressor cell activity and renal allograft function, definitive conclusions cannot be made because of the
high degree of variability of the test results, and the small patient
population.

Thus, there appears to be a role for suppressor cells in

the prevention of renal allograft rejection; however, more sophisticated
tests are needed to accurately access the role of suppressor cells in
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the rejection process.
IVB.

Evaluation of the Effects of Three
Therapeutic Modalities on Renal Allograft
Function and Survival

IVB-1.

Effectiveness of Pretransplant Splenectomy
in Renal Allograft Function and Survival
Since Starzl and his coworkers (125, 126) first suggested that

splenectomy might represent an additional method for preventing acute
rejection, several studies have been undertaken (127-131).

While a

majority of the studies have found splenectomy to be ineffective in
enhancing graft survival, our findings support those of Kauffman et al.
(131), who showed that splenectomy carried out prior to transplantation
enhanced graft survival.
ficant at P · < 0.05,

Our results, which are statistically signishow that only three of the thirty-one patients

(9.7 percent) who underwent a splenectomy suffered a rejection episode,
while eleven of forty patients (27.5 percent) who did not undergo a
splenectomy, suffered at least one rejection episode.

These results are

similar to Kauffman's group (131), who found that 93 percent of the
patients who underwent pretransplant splenectomy and 81 percent of the
patients who had their spleen removed at the time of transplant, did not
experience a rejection episode; whereas, 48 percent of the patients not
undergoing splenectomY suffered at least one acute rejection episode.
An earlier study by Berne et al. (191) had presented evidence that)
while not statistically significant, was highly suggestive of improved
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one-year-graft survival with pretransplant splenectomY; sixty-six
percent one-year-functional-graft survival with splenectomy, as
compared to forty-nine perecnt without splenectomy.
These findings contradict the earlier studies of Bennett et

~

l128) and Opelz and Terasaki (129), who observed no significant difference in the occurence of rejections, whether or not a patient had a
splenectomy.

However, their conclusions were based on splenectomy being

carried out at the time of transplanatation; this procedure has subsequently been shown by Kauffman and his coworkers (131) to be ineffective in enhancing graft survival.

Furthermore, several of the studies ·an

the effectiveness of splenectomy for graft survival were carried out in
tne early 1960's, when many of the graft failures were attributable to
sepsis and ineffectual management of the immunosuppressed patient.
A second point raised by our studies is that splenectomy appears
to be without influence on the renal function of transplant patients
wnom have not experienced a rejection episode within one-year of the
test date (Table 13).

In addition, transplant patients who have

suffered a rejection episode early in their posttransplant history, but
at the time of testing had excellent functioning grafts, have statistically eqivalent (P

>

0.5) renal function values whether or not

splenectomy was carried out.

However, this does not preclude the

possibility that splenectomy had a positive effect early on the renal
function and survival of these patients.
An interesting finding of our studies is that patients who had
a splenectomy and have normal renal function, have significantly greater
total lymphocytes ( P = 0.00) and B-cells ( P = 0.04 ) , than
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similar patients who did not undergo splenectomy.

T-cell numbers for

both groups (Groups I and II, Table 14) are almost identical.

Similar

results have been reported by Veith et al. (127) and Bischel et al.
(192).

Bischel and her colleagues showed that both the white blood

cell count and azathioprine dosage of twelve patients who had undergone
splenectomy was significantly higher on the thirtieth post-transplant
day, than fifteen patients who had not undergone splenectomy.
The mechanism by which splenectomy appears to improve renal
allograft survival is as yet unknown; however, it appears that splenectomy might exert its suppressive effects on both the humoral and cellular arms of the rejection process.

The possibility that splenectomy

interferes with immunoregulatory responses to the graft has been suggested by Enomoto and Lucas (193); however, their proposal does not appear
to be supported by other studies in rodents (194, 195), or by clinical
surveys (127, 129}.

While it is possible that splenectomy interferes

with regulatory interactions of various suppressor T lymphocytes on the
one hand, and effector T lymphocytes and B lymphocytes on the other,
the overall effect of splenectomy appears to be a reduction in the
strength of the rejection response (195).
The mechanism whereby the humoral immune response is suppressed
might be that the spleen is an important site for antigen trapping and
clonal proliferation, i.e., proliferation of antibody-producing cells
(195).

Thus, under normal conditions, antigens in circulation are

trapped by the spleen where they can invoke the proliferation of antibody-producing cells.

However, after splenectomy, there is no spleen

to trap the antigens, and they are subject to degradation by the liver.

Evans et

~-
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(195) have attempted to test this hypothesis by diverting

venous return from the graft directly into the portal circulation;
however, graft survival was not improved by this procedure.

It is

possible that to degrade these antigens, several passages through
the liver are required.
IVB-2.

Enhancement of Renal Allograft Function and Survival with
Pretransplant Transfusion
Since the report by Opelz and Terasaki (132) first showed

that blood transfusions were effective in improving renal allograft
survival, a majority of studies now confirm that transfusions given
prior to transplantation improve graft survival.

Studies in our

laboratory show that patients who did not' undergo transfusion prior
to transplantation were twice as likely to experience a rejection
episide (eight out of thirty patients or twenty-seven percent), as
patients who had a pretransplant transfusion (six out of forty
patients or fifteen percent).
by Hunsicker et

~-

(144).

Similar results have been obtained

They showed that patients who had a

pretransplant transfusion exhibited a graft survival rate of
seventy-nine percent at three months, seventy-one percent at the
end of one year, and fifty-five percent at the end of three years
post-transplant.

This compared to a survival rate of fifty-five

percent at three months, forty-four percent at one year, and thirtysix percent at the end of three years for patients who did not
undergo a pretransplant transfusion.
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Since their study was retrospective and not randomized, a
comparison of transfused and nontransfused patients was carried out
to determine if other factors such as age and sex of the allograft
recipient were responsible for the improved graft survival observed
in the transfused group.

While significant differences were observed

between the two groups, stratification of Hunsicker's data (Figure 8)
for these factors, as well as for the influence of the original
cause of renal failure and the transplant date, still showed a
strong correlation between transfusion and graft survival.

While

our study of additional factors was not as extensive as that of
Hunsicker et

~-

(144), we also found that neither the age, nor sex

of the graft recipient was significantly responsible for the
improved graft survival.

Thus in the cas·e of cadaver transplants,

transfusion(s) appear to exert a positive effect.
In the case of living-related transplants, Solheim and his
co-workers (142) have demonstrated superior graft survival in
transfused patients with one-mismatched halotype (halotype refers
to a HLA antigen); whereas, blood transfusions given to patients
with HLA-antigens identical to the graft donor, appear to be
without influence.

In a similar study, Solheim and co-workers

(196) have shovm this to also be the case in cadaver transplants.
In an attempt to explain this findings, Keown and Descampes (197)
have proposed that the beneficial effects of transfusion are mediated
by strong

11

non-specific 11 immunological effects.

However, at this

time there is insufficient data to support or refute their
hypothesis.
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LEGEND

Figure 8.

Comparison of Non-transfused and Transfused Patients
from Table 1 of Effect of Blood Transfusions on Cadaver
Renal Allograft Survival, Hunsicker et ~· (144).

Comparison of Nontransfused and Transfused Patients
No Transfusions

No. of Patients
Age§
Male/Female
Months on Dialysis§
Bilateral Nephrectomy
Pretransplant Hematocrit

§

Pretransplant WBC§
HLA Ag Mismatches§
Cytotoxic Ab (> 10 %)
Immediate Graft FUnction

42

109

31 + 13

35 + 12

*
*

70/39

9.7 + 10.7

15 .8 + 15 .o

0.02

3/42

44/109

0.002

25 % + 7

20 % + 6

0.001

6200 + 2000

7200 + 3400

2.6 + 1.13

2.21 + 0.99

2/42

13/109

38/42

71/109

Differences not statistically significant
Means given + 1 SD

Probability

33/9

*.
§

Transfusions

*
*
*
0.004

0
1.0
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Another interesting finding of our results is that both the
creatinine and creatinine clearance values for transfused, nonrejecting patients (Group I, Table 16) were significantly better than
thos~

of the nontransfused, nonrejecting patients (Group II).

Since both

groups contained patients who had experienced an acute rejection episode early in their transplant history. but at the time of testing had
excellent functioning grafts, their values were independently accessed
(i.e., transfused, early, acute rejection patients and nontransfused,
early, acute rejection patients) to determine if they were responsible
for the differences in creatinine and creatinine clearance values
(Table 16).

However, evaluation of the latter groups (Groups III and

IV, Table 22), indicates that their values are not significantly
different from the former groups (Groups 'r and I I, respectively,
Table 16); and, therefore, it appears that the difference in creatinine and creatinine clearance values for transfused and nontransfused,
nonrejection patients, can be attributed to the beneficial effects of
pretransplant transfusion.

Blood Urea Nitrogen (BUN) values were

similar for both nonrejection groups, as were the lymphocyte, T-cell
and B-cell numbers (Tables 16 and 17).
While a majority of the studies support the practice of administering transfusions prior to the transplant, there appears to be
a discrepancy over what number of transfusions provide the maximum
benefit.

Our results (Table 23) show that the number of transfusions

had no effect on whether or not a patient suffered a rejection episode.

However, only two of the fourteen patients who suffered a

rejection episode subsequently lost their kidney; and eight of the

TABLE 22
~

Comparison of Renal Blnction \alues fot the Effects of Pretransplagt
Transfusion on Early, Acute Rejectiona and Non-Rejection Patients
Renal function
Test

Creatinine

Transfused
Non-Rejection
Patients
(Group I)

Non-Transfused
Non-Rejection
Patients
(Group II)

1.3+0.4

1.6 + 0.4

N

= 77

21.1 + 7.7

BUN

N
Creat. Clearance

= 72

21.2 + 8.4

= 78

76.1 + 26.3
N

N

N

= 72

67.1 + 17.8

= 73

N

= 67

Transfused
Early Acute Rejection Patients
(Group III)

1.3+0.6
N

=4

26.5 + 12.4
N

=4

55.5 + 22.0
N

=4

Non-Transfused
Early Acute
Rejection Patients
(Group IV)

1.8 + 0.4
N

=

11

29.5 + 8.5
N

= 11

61.9 + 16.8
N

= 11

a
Groups III and IV represent patients who experienced an acute rejection episode early in
their transplant history, but at the time of the test date (within one month of the test)
had excellent functioning grafts.
b

Values obtained from Table 16
N refers to the number of tests

........
........
........
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TABLE 23
Effects of Transfusion on Acute Rejection
Transfusion

Rejection

Non-Rejection

a
21.5 %

29.7 %

7.0 %

5.4 %

Post transplantation

14.3 %

2.7 %-

Not transfused

14.3 %

35 .1 %

Pre- and During
transplantation

7.0 %

5.4 %

Pre- and Post
transplantation

21.5 %

16.2 %

During and Post
transplantation

14.3 %

2.7%

Pre-transplant
During transplantation

b

Pre-, During, and Post
transplantation

0

%

2.7 %

Transfused once

0

%

d
8.3 %

Twice to five times

58.0 %

50.0 %

Greater than five times

42.0 %

41.7 %

a
Fourteen patients in this group
b

Thirty-seven patients in this group
c

Twelve patients in this group
d

Twenty-four patients in this group

fourteen had normal renal function at the time of the test.
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Hunsicker

et al. (144) found that maximum graft survival at three months posttransplant occurred with as few as three units of blood.

Feduska et al.

(152) reported maximum beneficial effects with five transfusions.

On

the other hand, other studies have shown that maximum graft survival
occurs with larger numbers of transfusions.

In a study made by the

National Institute of Allergy and Infectious Diseases (NIAID) which
included more than 1,500 patients and some forty medical centers, oneyear graft survival was shown to increase from 37 percent in patients
who had received no transfusions, to 50 percent in patients who had
received one to five transfusions, and to 56 percent in patients receiving six to ten transfusions (198}.

Opelz and his coworkers (146)

demonstrated significant beneficial effects with more than twenty
transfusions.
Finally, Solheim and coworkers (142) found that, whereas
cadaver transplant survival was influenced by the number of transfusions

(196), the number of blood transfusions in living-related transplants
did not influence graft survival.
In addition to the number of transfusions which a prospective
transplant patient receives, another factor which has been investigated
for its possible effect on graft survival is the nature of the blood
transfused.

Whereas, Opelz and Terasaki (150) found frozen blood to be

less effective than packed cells or whole blood, Polesky et al. (199),
and Hunsicker et al. (144), found there was no difference in the outcome between patients receiving frozen erythrocytes and those receiving
other blood preparations.

While our study did not examine the effect

114

of the different blood types on graft survival, it should be pointed
out that patients who received multiple transfusions received a number
of different blood transfusion types, depending on their physiological
and/or immunological status.
One final factor which may have an affect on graft survival
is the blood type of the recipient who is receiving the pretransplant
transfusion.

A study made by Joysey et al. (200) found that the bene-

ficial effect of transfusion was restricted to patients of the blood
group 11 0. 11 Bore et al. (201) found a significant improvement in the
one-year-graft survival rate of transfused patients of the blood type 0
(81 percent for transfused patients, compared to 38 percent for untransfused patients), as compared to A, Band AB transfused patients {55
percent for transfused patients compared to 39 percent for untransfused
patients).

Our study, which consists of too small a population to

yield statistically-significant results, strongly indicates superior
reduction in acute rejection for transfused 0 patients (zero out of
eleven, or zero percent for transfused 0 patients compared to one out
of two, or fifty percent for nontransfused 0 patients), as compared to
A, B-and AB transfused patients (six out of fourteen, or 43 percent for
transfused A, Band AB patients, compared to five of twelve for nontransfused A, B and AB patients).

These results suggest the blood

group, or a factor closely related to it, determines the fate of the
grafted kidney (201).

Opelz and his coworkers (202) have suggested

that the harmful effects of cytotoxic antibodies may be restricted to
certain recipient blood groups.

However, since the 0 blood group is

a homogenous group in that it only received 0 blood transfusions, whereas
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A, Band AB patients are nonhomogenous groups, further studies need to
be carried out before conclusions about the effect that a patient•s
blood type has on his or her chances of having a successful transplant
can be drawn.

To illustrate this point, Opelz and coworkers (202)

recently demonstrated that the blood group of the recipient (0 or non0) presented no advantage in the twelve-month graft survival of transfused patients.
While there has been a good deal of work done on the various
effects of blood transfusions on graft survival, little is known about
the mechanism(s) involved in the graft-protective effects.

Of the

several mechanisms suggested, two major categories can be constructed.
The first category would consist of a 11 Selection mechanism, 11 in which
either a patient or donor would be secluded from the transplantation
procedure.

Some patients who receive transfusions respond by making

antibodies that react with cells from potential donors.

Thus, trans-

fusion might constitute a method of identifying individuals who produce
extremely strong antibody reactions, and might consequently be highrisk graft recipients, eliminating them from the transplantation pool.
On the other hand, if the antibody response is weak, transfusion would
allow for the selection of more compatible donors.

It is of interest

to note that HLA-A and B antibodies have been ascribed both beneficial
effects (202), no effect (133, 149), or even deleterious effects (135)
on first cadaveric-kidney grafts provided a negative crossmatch.

Recent

studies by the Southeastern Organ Procurement Foundation (SEOPF) and
the NIAID, have shown that while there is a small, but significant improvement in one-year kidney survival roles in cases where there is a
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good match of HLA-A and B antigens of the donor and recipient; however,
it appears from the SEOPF study that transfusion makes a larger contribution to one-year-kidney graft survival than does a well-matched
HLA-A and B donor-recipient pair (198).

According to G. Melville

Williams, who presented some of the SEOPF data at the 7th International
Convocation on Immunology, the effects of transfusion and antilymphocyte serum (see next section) appear to occur within the first
six months after transplantation, a time when about 50 percent of the
graft rejections occur.

The positive effects of HLA-A and B matching

do not become apparent until twelve to eighteen months posttransplant,
when a good match appears to have a stabilizing effect on the survival
of kidneys that made it through the earlier, more hazardous time (198).
Before discussing the second mechanism of.graft improvement, it should
be pointed out that recent studies suggest that the matching of another
HLA antigen, D-related (DR), appears to be more important for kidneygraft survival than either HLA-A or B matching; however, additional
studies are required to verify these early observations.
The second mechanism which has been suggested, includes both
specific and non-specific immunological mechanisms.

Specific immune

mechanisms include enhancement, i.e., process by which serum-blocking
antibodies prolong graft survival, and tolerance, i.e., denotes a
condition of unresponsiveness caused by the elimination or inactivation
of responsive cell clones (T-cell orB-cell) and/or by suppressor T-cells.
Although B-cell antibodies have been found in the sera of transfused
patients prior to and following transplantation, it is unlikely that
antibodies directed against DR antigens for which donor and host are
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disparate, could be solely responsible for graft
just a single transfusion (144, 203).

impr~vement

after

In addition, recent data indi-

cates that anti-HLA-DR antibodies can induce hyperacute or accelerated
rejection (204).

For the same reason, (efficiency of a single trans-

fusion), prolonged graft survival is unlikely to be due to the presence
of antiidiotypic antibodies, i.e., antibodies directed against antigenic
determinant unique to the antigen-binding region of an immunoglobulin.
However, the possibility exists that other 8-cell antibodies induced
by blood transfusions, e.g., cold cytotoxins, might be responsible for
prolongation of graft survival (205).
Another possible mechanism is that giving transfusions pretransplant and during transplants results in a state of unresponsiveness
or tolerance, which decreases the chances.of recipient rejection, and,
therefore, prolonged graft survival.

Five possible mechanisms of

tolerance induction are depicted in Figure 9 (206).
antigen-specific process.

Tolerance is an

Since transfusion is not-donor specific,

it is unlikely that tolerance is responsible for the improved graft
survival.

Nevertheless, reduced cell-mediated lympholysis activity is

seen in particularly successful renal allograft patients, suggesting
that for these individuals some form of tolerance exists (207).

Mixed

lymphocyte culture experiments (see Section IA-4) have shown that
suppressor cells can be activated in vitro by specific (antigen) and
nonspecific (mitogen) means.

Thus, it is possible that transfusion

induces a state of tolerance in the recipient by nonspecifically activating suppressor cells.
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L~E~

Figure 9.

Possible mechanisms of tolerance induction.
Schematically represented is the immune response and
five possible mechanisms of induction of tolerance.
These include: 1) clonal elimination of the potentially
responding T or B cell population; 2) activation of
suppressor T cells specific for the tolerogen; 3)
presence of blocking antibody that prevents further
antigen stimulation; 4) production of an antibody to
idiotypic (antireceptor) that blocks further
activation of antigen specific T or B cells that bear
that receptor; and 5) catabolism of the antigen that
bypasses normal immune recognition or induction
processes.
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MECHANIS.\fS OF TOLERAI\'CE

Immune Tolerance
I Clonal Elimination

II Suppressor Cells

IV Anti - ldiotype (Network)

A93

+

V Antigen Catabolism
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As for nonspecific mechanisms, Keown and Descamps (197) have
suggested two mechanisms whereby erythrocytes can nonspecifically
depress the immune system of the transfused patient, thereby prolonging
graft survival.

The first mechanism would involve phagocytosis and

lysis of red blood cells impeding the coincident or subsequent processing of antigen by mononuclear phagocytes, thus impairing antigen
presentation and lymphocyte activation.

Such inhibition could be

attributed to a transient blockade of phagocytosis, interference with
mechanisms intrinsic to antigen degradation (208), or to the more
fundamental inhibition of cellular metabolism via the regulation of
cation transport by ferric ions (209). The observation that Fe(+ 3)
alone, at concentrations equivalent to that present in hemoglobin,
exerts an equally-powerful depressive effect on antigen stimulation
(210), argues in favor of this mechanism.

The other mechanism, in-

volves the production of an immunoregulatory messenger by mononuclear
phagocytes which have been induced by the endocytosis of red blood cells.
The messenger could be prostaglandin-related.

Prostaglandins are

rapidly produced in vitro after endocytosis of red blood cells (211);
and their derivatives have been shown to inhibit the generation of
cell-mediated cytotoxicity in vivo, and prolong allograft survival
(212, 213).

Solheim and coworkers (142) argue against a strong non-

specific mechanism, based on observation that neither graft survival nor
first rejection frequency is affected by blood transfusions in HLAidentical transplants.

However, significant improvement in graft func-

tion and survival in HLA-identical transplants might not be expected
since this combination of transplants manifests less rejection.

Thus,

it appears that a nonspecific mechanism for

allograf~

prolongation is
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plausible; however, additional studies with pure erythrocytes, i.e.,
devoid of HLA-antigen containing reticulocytes, are needed to resolve
the mechanism.

In addition, the fact that suppressor cells have been

shown to depress cell-mediated responses (16, 20, 57-63), and can be
induced by nonspecific means (22), suggests that suppressor cells may
play an important role in renal allograft prolongation.
IVB-3.

Role for Antithymocyte Globulin in
Renal Allograft Survival
Since Starzl and his coworkers (153) first used antilympho-

cyte globulin (ALG) in clinical renal transplants, several studies
(154-162) have been carried out to determine what effects ALG or antithymocyte globulin (ATG) have on graft function and survival, when used
in place of, or more commonly, as an adjunct to conventional immunosuppressive therapy.

While some of the studies show improvement in

graft function and survival (153, 158, 163), the majority of studies
have been unable to demonstrate any significant improvement in graft
function and/or survival with ALGor ATG (156, 159, 160-162).

In

addition, ALG and ATG have been shown to cause severe immunological
reactions (214-217), necessitating their premature discontinuation.
Our study indicates that fewer patients treated with ATG experienced acute rejection (four out of nineteen patients, or 21 percent) than patients not receiving ATG (ten out of thirty-three, or
30 percent).

In addition, none of the patients who were treated with

ATG, and experienced an acute rejection episode, suffered loss of their
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kidney graft; whereas, two of the ten patients who had a rejection
episode, and did not receive ATG, lost their graft.

While our results
on graft rejection are not statistically significant ( x2 = 0.52)

for one degree of freedom), they do suggest that the treatment of
patients with ATG decreases their chances for graft rejection.
findings have been made by Taylor et al. (158).

Similar

In their study, they

found that patients treated with ALG (20 mg/kg/day) intravenously, in
addition to their standard immunosuppressive therapy, experienced less
than half the number of acute rejection episodes, and had betteraccumulated graft survival.

Furthermore, they found that patients

treated with ATG had significantly better renal function (serum creatinine and creatinine clearance) values at both one-month and two-months
posttransplant, than non-ATG-treated patients; however, the renal
function values at one-year posttransplant were the same for the two
groups.

Our results (Table 19) show that nonrejecting-transplant

patients (Groups I and II) have almost identical renal function values
whether or not they received ATG.

However, these two groups of patients

have mean posttransplant times of fifteen months and 17.8 months, respectively; therefore, our results agree with those of Taylor et al.
(158).

Moreover, examination of the two rejection groups (Group III

and IV), which have mean posttransplant times of 2.5 months and 1.5
months, respectively, demonstrates that ATG had a slight, but positive
effect on renal allograft function.
The results in Table 20 demonstrate that ATG is without influence
on the total lymphocyte number, T-cell number, and B-cell number of nonrejection patients (Groups I and II).

However, ATG treatment does appear
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to have a positive effect on the total lymphocyte number, and especially on the T-cell number of rejection patients (Group III).
results had been earlier reported by Birkeland.et

~

Similar

(218).

A possible explanation for the conflictive nature of the
benefits of ATG treatment might be that the previous studies have used
ATG only as an adjunct to conventional steroid therapy.

In order to

accurately access the potential of ATG, experiments must be carried out
in which ATG is used in place of high-dose steroid therapy.

Such a

study has been recently carried out by Shield et al. (163).

Patients

were initially treated with azathioprine and prednisone.

With the onset

of acute rejection, patients were randomly assigned to additional
treatment with either ATG or high-dose steriods.

Eight of the ten

patients treated with ATG had prompted reversal of acute rejection.
All ten of the patients treated with high-dose steroids had prompted
reversal of acute rejection; however, four of the patients required
irradiation of the graft and actinomycin treatment.

Furthermore, five

of the patients required treatment for second and third rejection
episodes.

A fourteen-month followup found nine of the ten patients

treated with ATG having functional allografts, with eight of the nine
showing normal renal function.

On the other hand, nine of ten patients

treated with high-dose steroids had function grafts, but renal function
remained impaired in three.

Therefore, it appears that the major ad-

vantage of using ATG is that it decreases the number of second rejection
episodes, and also allows for the decreased use of high-dose steroids
which have been implicated in fatal diverticulitis, as well as several
other disorders.
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Finally, while ATG appears to be effective in reducing the
number of acute rejection episodes, its use on several occasions has had
to be curtailed due to the manifestation of severe immunological reactions.

In a recent report, Abdou·et al. (219) showed that deaggregated

ATG (dATG) prepared by centrifugation at 40,000 x g for one hour and
filtered through a 0.45 urn millipore filter, induced a state of tolerance in patients without the severe immunological complications seen
when aggregated ATG is used.

The tolerance induced by dATG appears to

be mediated by antigen-specific suppressor T-cells which carry receptors
for the horse serum, and lasts for a few weeks after dATG administration.
Therefore, it may be possible to treat acute rejection with dATG, thus
avoiding the negative side effects of ATG.

CHAPTER V
CONCLUSIONS
1.

Renal transplant patients who are within their first year of
transplantation display low suppressor lymphocyte activity.

2.

Renal transplant patients who have retained their grafts for
a period of time greater than one year display an average
suppressor lymphocyte activity which approaches the value
of healthy individuals.

3.

The suppressor lymphocyte assay used in our research is neither
precise or specific enough to predict a rejection episode.

4.

Acute rejection episodes take place in an environment of
reduced T and B lymphocyte numbers.

5.

Statistical analysis of the effects of splenectomy, pretransplant transfusion, and antithymocyte globulin (ATG)
administration on graft rejection show that only splenectomy
has a statistically significant effect on decreasing the
likelihood of a rejection episode.

However, it should be

pointed out that the Splenectomized-Non-Rejection Group
(Group II, Table 11) contains a greater number of individuals
who have received a donor graft from a living-related
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individual, than either the Transfused-Non-Rejection Group or
the ATG Administered-Non-Rejection Group (Table 11).

Since

transplantation with a living-related graft has been shown to
have a greater survival rate {90% graft survival with livingrelated grafts, as compared to a survival rate of 50% when the
donor organ comes from a cadaver), the decreased rate of
rejection episodes might be influenced to a greater degree by
the source of the graft than the therapeutic effect of the
splenectomy.
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